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SELEX, the process of selecting aptamers, is often hampered by the difficulty of 
preparing target molecules in their native forms and by a lack of a simple yet 
quantitative assay for monitoring enrichment and affinity of reactive aptamers. In this 
study, I established a new method to seek to discover DNA aptamers against human 
serum markers for potential therapeutic and diagnostic applications. To circumvent 
soluble expression and immobilization for performing SELEX, I ectopically expressed 
soluble growth factors on the surface of yeast cells to enable cell-SELEX and devised 
a flow cytometry-based method to quantitatively monitor progressive enrichment of 
specific aptamers. High-throughput sequencing of selected pools revealed that the 
emergence of highly enriched sequences concurred with the increase in the percentage 
of reactive aptamers shown by flow cytometry. I first tested if the yeast-surface 
display works as a platform for examining bindings of aptamers to target proteins. 
Afterwards, I particularly selected DNA aptamers against VEGF were specific and of 
high affinity (KD = ~ 1 nM), and demonstrated a potent inhibition of capillary tube 
formation of endothelial cells, comparable to the effect of a clinically approved anti-
VEGF antibody drug, bevacizumab. I also have successfully selected DNA aptamers 
against PDGF-A, PDGF-B. Considering the fact that many mammalian secretory 
proteins have been functionally expressed in yeast, the strategy of implementing cell-
SELEX and quantitative binding assay can be extended to discover aptamers against a 
broad array of soluble antigens. 
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CHAPTER 1 
 
INTRODUCTION 
 
Cancer and Growth Factors. 
 
Cancer refers to a group of different diseases which are characterized by 
abnormal growth and spread of malignant cells. The causes of cancer are multifaceted, 
arising from both internal and external factors, which result in detrimental alteration of 
normal gene expressions and/or protein expressions. These phenomena cause cells to 
obtain increasingly abnormal proliferation and invasion. For instance, induction of 
uncontrolled cell growth leading to cancer can occur when the protein expression 
levels or post-translational modification patterns are altered and/or when there is an 
incidence of genetic abnormality [1].  
In physiological conditions, cells receive fate-determining signals from the 
surrounding tissues, primarily in the form of polypeptide growth factors. The 
foundation and the first building block of tissue homeostasis is the organized 
integration of these extracellular signals. After the departure and float from 
homeostasis, tumor initiations are associated with oncogenic mutations. Afterwards, 
growth factors are the major regulators of all subsequent steps of tumor progression 
and invasion, namely metastasis, invasion across tissue barriers, angiogenesis, and 
colonization of distant locations [2]. Angiogenesis is the formation of new blood 
vessels. This process involves the migration, growth, and differentiation of endothelial 
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cells which line the inside wall of blood vessels. Angiogenesis plays a critical role in 
the growth and spread of cancer. A blood supply is necessary for tumors to grow 
beyond a few millimeters in size. Tumors can cause this blood supply to form by 
giving off chemical signals that stimulate angiogenesis. Tumors can also stimulate 
nearby normal cells to produce angiogenesis signaling molecules. The resulting new 
blood vessels “feed” growing tumors with oxygen and nutrients, allowing the cancer 
cells to invade nearby tissue, to move throughout the body, and to form new colonies 
of cancer cells, called metastases. 
Once initiated by driver mutations, pre-malignant epithelial cells may accumulate 
additional oncogenic mutations, but their expansion and progression to metastatic 
carcinomas depend on a multi-step process orchestrated primarily by growth factors 
(GFs) (Figure 1-1). The multi-step process contains: 1) Driver mutation, 2) Clonal 
expansion, 3) Carcinoma in situ or intraepithelial neoplasia, 4) Invasion, 5) 
Dissemination, 6) Micrometastases, 7) Resistant clones after chemotherapy or 
radiotherapy, 8) Angiogenesis, and 9) Metastasis. GFs are polypeptides [3] bind to 
transmembrane receptors mediating kinase activity [4] to stimulate specific 
combinations of intracellular signaling pathways [5-7]. These cellular activations and 
the respective GFs are co-opted in several phases of tumor progression [8]. The 
metastatic process enables GFs to support tumor progression [9, 10].
 3 
 
1
 
 
 
                                                 
1
 This figure is modified and reproduced from the article originally published in Physiology (Esther 
Witsch, Michael Sela, and Yosef Yarden. Physiology (Bethesda). 2010 April; 25(2): 85–101. 
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Figure 1-1. The stepwise progression of cancer and roles for growth factors. 
The process is initiated by a somatic mutation that gives considerable survival and 
growth advantages to the initiated cell (Step 1). GFs such as Epidermal Growth Factor 
(EGF) and Insulin-like Growth Factor 1(IGF1) support the followig expansion of 
mutation-bearing clones (Step 2), and the event usually leads to intraluminal lesions 
(Step 3), such as carcinoma in situ or intraepithelial neoplasia, which are surrounded 
by the basal membrane. Invasion (Step 4) refers to the migration and penetration into 
neighboring tissues of cancer cells. Cancer cells enter (extravasation) and exit 
(intravasation) lymphatic and blood vessels to disseminate (Step 5) and metastasize to 
distant organs or tissues. Extra- and intravasation entail the supporting functions of 
macrophages, platelets, and endothelial cells. The resulting micrometastases (Step 6) 
are usually sensitive to chemotherapy and radiotherapy. However, the new mutations 
and the ability of cancer cells to produce GFs (autocrine loops) improve the growth of 
resistant clones (Step 7). Angiogenesis (Step 8) is essential for the establishment of 
secondary tumors. Both sprouting of existing vessels and recruitment of bone marrow-
derived endothelial progenitor cells are stimulated by GFs secreted by tumor and 
stromal cells. At the final stage, relatively large metastases (Step 9) populate a definite 
set of target organs. Note that a latency period of several years may precede this final 
phase.  
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Tumor cells have an absolute requirement for a persistent supply of new blood 
vessels to nourish their growth and to facilitate metastasis. Thus, tumor vascularization 
is a pivotal process for the progression of a neoplasm from a small localized tumor to 
an enlarging tumor with the ability to metastasize [11]. The growth of human tumors 
and development of metastases depend on the de novo formation of blood vessels. The 
formation of new blood vessels is tightly regulated by specific growth factors that 
target receptor tyrosine kinases (RTKs)[12]. Vascular endothelial growth factor 
(VEGF), Platelet-derived growth factor (PDGF), and the Fetal Liver Kinase 1 (Flk-1)/ 
Kinase insert domain receptor (KDR) RTK have been implicated as the key 
endothelial cell-specific factor signaling pathway required for pathological 
angiogenesis, including tumor neo-vascularization [12].  
 
Angiogenesis and Cancer 
 
The generation of new vessels is critical for tumor growth beyond few 
millimeters of size. New vessels are formed either by mature endothelial cells 
(angiogenesis)[13] or by bone marrow-derived endothelial progenitor cells (EPCs)[14], 
which are home to foci of angiogenesis (vasculogenesis)[15]. Growth factors like the 
vascular endothelial growth factors (VEGFs), FGFs [16], and TGF-β play important 
roles in both vasculogenesis and angiogenesis, and VEGF antagonists limit 
angiogenesis in animals and in patients. EPCs regulate the angiogenic switch via 
paracrine secretion of proangiogenic growth factors and by direct luminal 
incorporation into sprouting nascent vessels [17]. Mobilization of circulating 
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progenitors and other endothelial cells to tumors emerges as a critical step in tumor 
progression.  
Transcription level of VEGF mRNA is also induced by different growth factors 
and cytokines, including PDGF, EGF, tumor necrosis factor alpha (TNF-α), and 
interleukin 1-beta [18, 19]. The initial step of transcription induced by hypoxia in 
tumor growth and factor secretion by the growing tumor and the stromal tissue leads 
to an upregulation and activation of growth factor receptors. Results in endothelial 
sprouting, increased vascular permeability, the expression of tissue matrix 
metalloproteinases (MMPs), and eventually the digestion of matrix, which is required 
for the endothelial cell to move [12]. The increased mitogenesis of endothelial cell and 
spread and activation of other factors lead to the formation and travel of endothelial 
cells, including other supporting cells, and eventually lead to vessel extension, 
increased capillary integrity, differentiation of micro-vessel support cells, and 
formation of the vascular network. VEGF plays a role in the earliest events in this 
process. 
The PDGF signaling system has been proven that it contributes to tumor 
angiogenesis and vascular remodeling. In the study of Xue et. al. [20] suggested that 
PDGF-BB–induced erythropoietin (EPO) promotes tumor growth through two 
mechanisms: 1) paracrine stimulation of tumor angiogenesis by direct induction of 
endothelial cell proliferation, migration, sprouting and tube formation, and 2) 
endocrine stimulation of extramedullary hematopoiesis by inducing erythropoietin 
production in stromal cells leading to increased oxygen perfusion and protection 
against tumor-associated anemia (Figure 1-2). 
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2
 This figure is modified and reproduced from the article originally published in Nature (Napoleone 
Ferrara & Robert S. Kerbel. Nature. 2005 438, 967-974). 
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Figure 1-2. A, Tumor cells produce VEGF-A and other angiogenic factors such as 
bFGF, angiopoietins, interleukin-8, and VEGF-C. These stimulate resident endothelial 
cells to proliferate and migrate. B, An additional source of angiogenic factors is the 
stroma cells. This is a heterogeneous compartment, comprising fibroblastic, 
inflammatory and immune cells. VEGF-A or PlGF may recruit bone-marrow-derived 
angiogenic cells (BMC). Tumor cells may also release stromal-ell-recruitment factors, 
such as PDGF-A, PDGF-C or transforming growth factor β (TGF-β). A well-
established function of tumor-associated fibroblasts is the production of 
growth/survival factor for tumor cells such as EGFR ligands, hepatocyte growth factor 
and heregulin. C Endothelial cells produce PDGF-B, which promotes recruitment of 
pericytes in the microvasculature after activation of PDGFR-β.  
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In the gene expression level, Westphal et. al. have studied the expression of a 
panel of angiogenic factors, and of the angiogenesis inhibitor angiostatin, in a panel of 
human melanoma cell lines giving rise to xenografts with different vascular densities 
[21]. In their study, expression of basic fibroblast growth factor (bFGF) and VEGF 
was clearly correlated with a high degree of vascularization, confirming the 
importance of these factors for tumor angiogenesis [21]. In addition, there was 
exclusive or elevated in vitro expression of angiogenic factors interleukin 8 (IL-8), 
PDGF-AB, and, to a lesser extent, midkine in cell lines that formed highly 
vascularized tumors. A similar angiogenic-factor-expression pattern was found in the 
corresponding xenografts, with the exception of VEGF. In most cell lines, this factor 
had low expression in vitro which was strongly enhanced in vivo [21].  
From the above, every study provides evidence for the notion that regulation of 
tumor angiogenesis is dependent on multiple factors. Inhibition of angiogenesis for 
therapeutic purposes, therefore, should preferably not concentrate on a single factor. 
 
Therapeutic Strategies Related to Growth-Factor Inhibitors for Cancers 
 
The process of angiogenesis is controlled by chemical signals of growth factors 
in the body. These signals can stimulate both the repair of damaged blood vessels and 
the formation of new blood vessels. There are other chemical signals called 
angiogenesis inhibitors interfere with blood vessel formation[22]. Normally, the 
stimulating and inhibiting effects of angiogenic signals are regulated and balanced so 
that blood vessels form only when and where they are needed[23]. Pathological 
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angiogenesis is a hallmark of cancer and various ischaemic and inflammatory 
diseases[24]. To progress, angiogenesis is essential for tumor growth and metastasis, 
controlling tumor-associated angiogenesis is an effective method in limiting cancer 
progression and invasion. The tumor micro-environment comprises numerous 
signaling molecules and pathways that regulate the angiogenic response. 
Understanding how these components functionally interact to each other as angiogenic 
triggers or as suppressors and how the mechanisms of resistance arise is required for 
the identification of new therapeutic strategies. Growth blockers (also called cancer 
growth inhibitors) are a type of biological therapy and include tyrosine kinase 
inhibitors, proteasome inhibitors, mammalian target of rapamycin (mTOR) inhibitors, 
phosphoinositide 3-kinase (PI3K) inhibitors, histone deacetylase inhibitors and 
hedgehog pathway blockers. Achieving a durable and efficient anti-angiogenic 
response will require approaches to simultaneously or sequentially target multiple 
aspects of the tumor microenvironment[25]. Because tumors cannot grow beyond a 
certain size or spread without a blood supply, scientists are trying to find ways to 
block tumor angiogenesis. They are studying natural and synthetic angiogenesis 
inhibitors, also called anti-angiogenic agents, with the idea that these molecules will 
prevent or slow the growth of cancer. 
Inhibition of the VEGF tyrosine kinase signaling pathway blocks new blood 
vessel formation in growing tumors, leading to stasis or regression of tumor 
growth[12]. Advances in understanding the biology of angiogenesis have led to the 
development of several therapeutic modalities for the inhibition of the VEGF tyrosine 
kinase signaling pathway. A number of these modalities are under investigation in 
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clinical studies to evaluate their potential to treat human cancers. Such as SU5416, a 
novel synthetic compound, is a potent and selective inhibitor of the Flk-1/KDR 
receptor tyrosine kinase that is presently under evaluation in Phase I clinical studies 
for the treatment of human cancers[26]. Clinically, there are several effective cancer 
drugs are targeting VEGF and PDGF receptor tyrosine kinase signaling. Bevacizumab, 
an anti-VEGF antibody for treating cancer, has been commonly used for treating 
patients with first-line therapy for metastatic colorectal cancer[27]. Sorafenib, a 
multikinase inhibitor, targets both Raf and VEGF and PDGF receptor tyrosine kinase 
signaling have been developed and studied clinically[28]. CP-673,451 is a potent 
inhibitor of platelet-derived growth factor β-receptor (PDGFR-β) kinase- and PDGF-
BB-stimulated autophosphorylation of PDGFR-β in cells (IC50 = 1 nmol/L) being 
more than 450-fold selective for PDGFR-β versus other angiogenic receptors (e.g., 
vascular endothelial growth factor receptor 2, TIE-2, and fibroblast growth factor 
receptor 2)[29]. Pegaptanib sodium (Macugen), an anti-vascular endothelial growth 
factor (anti-VEGF) RNA aptamer, for the treatment of all types of neovascular age-
related macular degeneration (AMD)[30]. Thus, it is important to understand the 
physiology of VEGF and PDGF and their receptors as well as their roles in 
malignancies in order to develop antiangiogenic strategies for the treatment of 
malignant disease.  
 
Aptamers 
 
Aptamers are specific DNA or RNA short-oligonucleotides that have been 
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isolated from large random sequence pools for their ability to bind specific target 
molecules. Aptamers are selected via an iterative in vitro process called SELEX 
(Systematic Evolution of Ligands by EXponential enrichment) [31-33]. A typical 
SELEX round contains the following three steps:1) Binding: incubation of the library 
with the target, 2) Partitioning: separation of target-bound library sequences from 
unbound ones, 3 Amplification: generation of a new and selected pool of nucleic acids 
by making multiple copies of the sequences that bound to the target. These steps are 
then repeated in an iterative fashion to obtain an enriched pool and the target binding 
aptamers are identified via cloning and sequencing processes. After successful 
selections of aptamers, aptamers are cloned and individually sequenced. In recent 
years, the conventional SELEX approach has been significantly improved in reducing 
laborious handlings in several different manners; however, the selection of aptamers to 
multiple targets in parallel is not well established. Also, the laborious purification of 
target proteins at the beginning stage and cloning to sequence individual aptamers at 
the last step remain to be tedious. Selection of specific aptamers to intact cells, cell-
SELEX, was first achieved in 1997[34]. In cell-SELEX, SELEX methodology is used 
with a complex mixture of cells as potential targets. Ligands to multiple targets are 
generated simultaneously during the selection process, and the binding affinities of 
these ligands for their targets are comparable to those found in similar experiments 
against pure targets. The approach was originally designed for when the clear marker 
target is unknown; so far, live cells of different cancers have been used in this process. 
With the FDA-approved drug Pegaptanib sodium (Mucagen) now available, others, 
such as AS1411, (nucleolin aptamer in clinical trial)[35], aptamers will contribute 
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immensely in cancer therapy. 
 
Aptamer and Antibodies 
 
Being very alike to antibodies, aptamers can bind with high affinity and 
specificity to target molecules ranging from proteins to small peptides [36, 37]. Based 
on their capabilities of target recognition, selective binding, and affinity, aptamers 
have been likened to antibodies. However, aptamers, by their unique features, have 
more flexibility in their development and range of applications. Specifically, aptamers 
can be generated using a variety of conditions, and the time needed for the generation 
of aptamers by the SELEX process is relatively short. Moreover, the use of animals 
for antibody production can lead to batch–to-batch variation. However, aptamers are 
chemically synthesized, which eliminates the possible batch-to-batch variations 
associated with antibodies. Furthermore, chemical synthesis of aptamers permits the 
biochemical manipulation required to incorporate various functional groups and 
specific moieties without compromising the function of most aptamers. This 
phenomenon has been adopted for aptamer conjugation with drug molecules and 
nanomaterials and for the modification of nuclease resistance bases, such as locked 
nucleic acids and 2‘-O-methyl nucleotide analogues, to further enhance nuclease 
resistance when adopted for in vivo study[38, 39]. Other comparable qualities, such as 
long-shelf life, controllable or cyclical denaturation, and renaturation, have expanded 
the flexibility of aptamers in various experimental designs. Even with improved 
nuclease resistance, aptamers have low blood residence times compared to antibodies, 
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as well as low toxicity or immunogenicity (if any), and these are important features 
when used for in vivo applications such as imaging. The demand for diagnostic assays 
to assist in the management of existing and emerging diseases is increasing, and 
aptamers could potentially fulfill molecular recognition needs in those assays. 
Compared with the bellwether antibody technology, aptamer research is still in its 
infancy, but it is progressing at a fast pace. The potential of aptamers may be realized 
in the near future in the form of aptamer-based diagnostic products in the market. In 
such products, aptamers may play a key role either in conjunction with, or in place of, 
antibodies. It is also likely that existing diagnostic formats may change according to 
the need to better harness the unique properties of aptamers[40]. 
 
Organization of the dissertation 
 
In the dissertation, I proposed to develop a multiplex cell-SELEX by using yeast 
surface display (YSD) technique that will be used to select aptamers in parallel to 
many proteins, with the initial target protein set including splice variants and 
differently post-translationally modified versions of the same proteins, as well as 
unrelated proteins with different physical properties and cellular associations, and with 
physiological and patho-physiological value. I have chosen a set of growth factors 
who have been proved played pivotal roles in pathological angiogenesis involved in 
cancer. Our goal is to obtain multiple DNA aptamers for each of these proteins. The 
selected aptamers will then be incorporated into high-throughput protein 
capture/detection assays using pairs of aptamers to detect each protein with high 
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specificity. Additionally, the aptamers will be tested for their inhibitory effects with 
the idea that some of the selected aptamers could be developed into inhibitory 
molecular drugs or used for validation of target proteins in therapeutic intervention. 
This dissertation has been expected to have major impact on a wide variety of medical 
and life sciences research, since the multiplex SELEX method will enable rapid 
selection of many aptamers against a large set of proteins in a cost-effective way. 
Moreover, the approaches could be used to focus on various large collections of 
specific medically-relevant marker, and potentially be scaled up to the entire proteome. 
The selected aptamers will not only be used to develop detection/capture reagents, but 
they can serve as inhibitors to study the function of the target proteins in vivo and to 
validate potential drug targets. An overview of the chapters and appendix are given 
below.  
Chapter 1: Introduction. This chapter provides the background on current studies 
of cancer related growth factors, and the current strategies of cancer treatment 
established based on the importance of these growth factors. In this part, I also present 
the related knowledge that inspired our work (especially our preliminary studies on 
protein engineering, yeast-surface display systems, SELEX, and cell-SELEX), as well 
as an introduction to the overall content of this dissertation. 
Chapter 2: Aptamer Discovery Using Yeast Display Cell-SELEX for Cancer 
Detection and Intervention. In this chapter, I described the development of the new 
method of yeast-cell SELEX incorporated with Yeast Surface Display (YSD) system. 
By using the known DNA aptamer of PDGF-BB, Pap1[41], I first demonstrated the 
YSD system can be served as a protein immobilization platform for binding of target-
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specific aptamers. I also documented the pilot screening of yeast-cell SELEX with 
known DNA aptamers, PDGF-BB aptamer 1 (Pap1) and VEGF aptamer 7 (Vap7)[42], 
of PDGF-BB and VEGF-A spiked-in DNA aptamer library. 
Chapter 3: Discovering Aptamers by Cell-SELEX against Human Soluble 
Growth Factors Ectopically Expressed on Yeast Cell Surface. This chapter was 
modified from a submitted publication to PLOS ONE and granted permission for 
being documented in the dissertation. In the chapter, I delivered a completed yeast-cell 
SELEX for multiple targets of growth factors with several new DNA aptamers 
discovered. By combining the results of yeast-cell SELEX with high-throughput 
sequencing technology, I have discovered the enrichment ratio and progression of 
yeast-cell SELEX can be monitored by flow cytometry, and the sequencing reads of 
each aptamer cluster from high-throughput sequencing showed strong correlation to its 
binding affinity to targets. At the same time, I have successfully created and identified 
a novel and high-affinity DNA aptamers to VEGF, and the aptamer have showed 
significant inhibition to tube (Human umbilical vein endothelial cell, HUVECs) 
formation assay which is a biologic experiment of angiogenesis. 
Chapter 4: Conclusions and Future Work. This chapter provides an overall 
conclusion of the work presented in this dissertation, as well as suggestions for future 
research directions. 
Appendix I: This chapter documents the engineering of β1 I-like domain, additional 
work I have accomplished along the efforts on engineering integrin α I domains.
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CHAPTER 2 
 
APTAMER DISCOVERY USING YEAST DISPLAY CELL-SELEX 
 
Summary 
 
SELEX, the process of selecting aptamers, is often hampered by the difficulty of 
preparing target molecules in their native forms and by a lack of a simple yet 
quantitative assay for monitoring enrichment and affinity of reactive aptamers. In this 
study, I have applied the yeast surface display (YSD) system for cell-SELEX. First, I 
verified if the yeast surface display technique can successfully express our target 
proteins (PDGF-BB and VEGF) and serve as a platform of protein immobilization for 
aptamer binding. Afterwards, I performed a pilot yeast-cell-SELEX with known 
aptamers spiked-in ssDNA library. After nine rounds of selections, I successfully 
repeated the results from the previous published work and also selected new DNA 
aptamers for PDGF-BB. 
The newly selected DNA aptamers for PDGF-BB have been quantitatively 
validated by flow cytometry with KD=~30 nM and examined to specifically recognize 
PDGF-BB from structurally similar proteins. 
 
Introduction and Significance 
 
Aptamers are specific DNA or RNA oligonucleotides that have been isolated 
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from large random sequence pools for their ability to bind specific target molecules. 
Like antibodies, aptamers can bind with high affinity and specificity to target 
molecules ranging from proteins to small peptides [1, 2]. Moreover, aptamer have 
several advantages over antibodies, such as ease of handling, convenience of 
synthesis[3], breadth of potential targets, improved storage, and lack of 
immunogenicity. These features, in addition to their high affinity and specificity, have 
made them very promising in analytical, diagnostic[4], and therapeutic applications[5]. 
In fact, the first aptamer-based drug, called Pegaptanib (mucagen)[6, 7], is now 
available on the market. This indicates that aptamers can also be used directly as drugs. 
Aptamers are obtained in vitro by a process called SELEX from a combinatorial 
library of DNA or RNA [8-10]. SELEX is an iterative procedure and often requires 
more than 10 successive cycles of selections and amplifications, where each SELEX 
cycle normally takes two days[11]. Each round of the selection comprises of several 
steps: 1) a random nucleic acid library containing 10
13
 ~10
15
 different sequences 
incubates with target proteins, 2) separating target-bound sequences from unbound 
ones, and 3) amplifying the selected ones for the next round. After successful 
selections of aptamers, aptamers are cloned and individually sequenced. In recent 
years, the conventional SELEX approach has been significantly improved in reducing 
laborious handlings in several different manners; however, the selection of aptamers to 
multiple targets in parallel is not well established. Also, the laborious purification of 
target proteins at the beginning stage and cloning to sequence individual aptamers at 
the last step remain to be tedious and time-consuming.  
Selection of specific aptamers to intact cells, cell-SELEX, was first achieved in 
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1997[12]. In cell-SELEX, SELEX methodology is used with a complex mixture of 
cells as potential targets. Ligands to multiple targets are generated simultaneously 
during the selection process, and the binding affinities of these ligands for their targets 
are comparable to those found in similar experiments against pure targets. The 
approach was originally designed for when the clear marker target is unknown; so far, 
live cells of different cancers have been used in this process. As a result, certain 
numbers of aptamers have been generated from most cancer cell lines [13-16]. 
However, extended therapeutic application is hard to accomplish due to the lack of 
information for targeting proteins.  
Yeast surface display (YSD) is a robust tool that has been employed successfully 
in isolating and engineering the affinity, specificity, and stability of antibodies[17-20], 
peptides[21], and proteins[22, 23]. YSD offers several advantages compared to other 
formats of display platforms such as phage display and the yeast-two hybrid method. 
Neither of these methods is effective for complex extracellular eukaryotic proteins, 
because of the absence of posttranslational modifications such as glycosylation and 
efficient disulfide isomerization. A protein of interest can be displayed on the surface 
of yeast by expression as a protein fusion to the Aga2p mating agglutinin protein. An 
extended advantage is that the quality control machinery of the yeast secretory 
pathway that routes mis-folded proteins into the degradation pathway ensures that 
proteins expressed on the surface are well folded. Furthermore, with YSD, displayed-
protein expressions, soluble-ligand bindings, and ligand-binding kinetics can be 
examined and measured by flow cytometry. In the context of protein production, flow 
cytometry assay simultaneously gives analysis data which rules out the need to 
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separate steps of protein expression and protein functional analysis. As for the 
measurement of ligand-binding kinetics, the common measurement methods in 
quantification of equilibrium binding constants and dissociation rate are surface 
plasmon resonance (SPR), electrophoretic mobility shifted assay (EMSA), and 
fluorescence polarization(FP). These methods have good sensitivity, but more works 
and time are required. Compared to the binding examination by flow cytometry, these 
three methods not only require protein purification, but also protein immobilization, 
probe labeling.      
Diagnostic procedures for cancer may include imaging, laboratory tests 
(including tests for tumor markers), tumor biopsy, endoscopic examination, surgery, 
or genetic testing. Imaging produces valuable pictures which can be used to detect 
tumors and other abnormalities, to determine the extent of disease, and to evaluate the 
effectiveness of treatment. Development of sensitive and specific molecular probe is 
still one of the main challenges in cancer imaging. In the context of molecular imaging, 
a variety of such probes have been developed [24-28]. Optical probes that yield high 
contrast target-to-background ratios are necessary to detect the micro-foci of cancer 
tumor. In general, aptamer probes have constant signals, while the image contrast is 
critically limited by a high background signals. Moreover, the cancer site can only be 
clearly observed after the physiological clearing of unbound aptamers, thus leading to 
a long diagnosis time, which further compromises the contrast by substantial 
consumption of bound aptamers. Therefore, ideal aptamer probes for in vivo cancer 
imaging should have high specificity targeting and high efficiency of clearance for the 
unbound probes. 
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Herein, I developed multiplexed-yeast-cell SELEX to select aptamers to many 
proteins in parallel. Taking advantage of next-generation-sequencing technology 
applied in this project, a thorough dataset from the sequencing result can be revealed 
to evaluate more candidates of aptamers. After aptamers are obtained, these aptamers 
will be adapted into target-activatable molecular probes of cancer imaging to enhance 
the contrast for in vivo diagnostic purpose. I expect these breakthroughs to accelerate 
current approaches of SELEX and facilitate molecular probes for cancer imaging. 
 
Experimental Procedures 
 
Procedure for yeast cell-SELEX  
An initial library of 10
15
 DNA aptamers spiked with PDGF-BB Aptamer 1 (Pap1) 
[29] and VEGF165 Aptamer 7 (Vap7) [30] was screened against yeast cells expressing 
target proteins. Reactive aptamers against growth factors were dissociated from the 
cells by incubation with 10 mM dithiothreitol (DTT) for 10 min at 25°C, which would 
reduce disulfide bonds between two subunits of agglutinin, thereby releasing Aga2 
and the bound aptamers from the cells. The mixture containing the aptamer complex 
was then cleaned up by a standard phenol-chloroform extraction and ethanol 
precipitation protocol [31], and amplified by PCR. The primer for the anti-sense 
strands to aptamers was phosphorylated at the 5’ end and was digested by lambda 
exonuclease (NEB) for 30 minutes at 37°C in 1X Lambda Exonuclease Reaction 
Buffer. To avoid chemical conjugation of aptamers with fluorescent dyes, I used 
phycoerythrin (PE)-conjugated streptavidin complexed with biotinylated 
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oligonucleotides (which I call ‘capturing oligonucleotides’) complementary to the 
constant region of the aptamers. After 4-10 rounds of SELEX, the aptamer pools were 
subject to high-throughput next-generation sequencing for bioinformatics analysis (see 
below). 
 
Flow cytometry for detecting antigen expression and aptamer binding in yeast 
Growth of yeast cells and induction of proteins was identical to the method 
described previously [21]. To verify the cell surface expression of target proteins, 5 μl 
of induced yeast culture was harvested, washed, and labelled at 30°C for 30 min with 
anti-c-Myc antibody 9E10 (ATCC), anti-HA antibody 3F10 (Roche Applied Science), 
or anti-VEGF antibody (R&D) as primary antibodies in labelling buffer (PBS, 0.5% 
bovine serum albumin (BSA), 10 mM MgCl2). After washing, cells were subsequently 
labelled at 4°C for 10 min with goat anti-mouse IgG-PE (Santa Cruz) or rabbit anti-
goat IgG-PE (Santa Cruz) secondary antibodies in labelling buffer. Cells were washed 
and re-suspended in 100 μl of labelling buffer and subjected to flow cytometry 
(Coulter Epics XL). To measure full-length aptamer binding to yeast, aptamers were 
first mixed with the biotinylated capturing oligonucleotides complementary to either 
5’ or 3’ constant regions, heated at 95°C for 5 minutes, and then gradually cooled 
down to room temperature for 20 minutes. To measure the binding of truncated 
aptamers to yeast, truncated variants were synthesized with biotin attached at the 5’ 
end. Aptamers with capturing oligonucleotides or biotinylated aptamers were then 
complexed with PE-conjugated streptavidin at a molar ratio of aptamer to streptavidin 
at 1:1. After washing, yeast cells were incubated with aptamer/streptavidin complex in 
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aptamer binding buffer (APBB; 10 mM HEPES, pH 7.9, 125 mM NaCl, 25 mM KCl, 
and 1 mM MgCl2). After washing, cells were re-suspended in 100 μl of labelling 
buffer and subjected to flow cytometry. The Hill equation was fit to data (mean 
fluorescence intensities vs. concentration of aptamers) using Prism 5 (GraphPad) to 
determine the equilibrium dissociation constants.  
 
High-throughput DNA Sequencing 
The aptamer pools after SELEX rounds of 0, 4, 8, and 10 were chosen and 
subjected to a high-throughput DNA sequencing. A small portion of the PCR products 
from each selected pool listed above were PCR amplified using the primers that 
contain a unique 9-mer barcode and the adapters necessary for the HiSeq 2000 
(Illumina) sequencing platform. High-throughput sequencing data derived from 
SELEX pools were filtered, clustered, and analyzed as previously described [32]. 
Processed sequences were analyzed separately for different pools, and those with 
>85% sequence identity were placed to the same clusters.  
 
Results 
 
To utilize YSD as a platform for immobilization of target proteins, proteins of 
interests are expressed at the yeast surface following a well-established protocol[19]. 
In short, a protein with either the N-terminal HA or the C-terminal c-myc epitope tag 
may be displayed on the surface of yeast by expression as a protein fusion to the 
Aga2p mating agglutinin protein. With the availability of the pNL6 plasmid, such 
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fusions can be expressed under the control of GAL1,10 galactose-inducible promoter. 
Aga1p is covalently attached to the cell wall via a phosphatidylinositol glycan tail, and 
Aga2p is disulfide bonded to Aga1p. The presence of the fusion protein on the cell 
surface may be detected of its ligand-binding activity by immunofluorescent labeling 
of epitope tags and examined by flow cytometry analysis. 
 
Validate the feasibility of YSD as a novel platform of cell-SELEX. 
To validate that YSD could be a new platform of cell-SELEX; a known DNA 
aptamer, Pap1 [29], screened from PDGF-BB protein has been synthesized and 
examined. Pap1 was being isolated from an 80-bp synthetic ssDNA library whose 
composition is a 40-bp variable region flanked by two 20-bp constant regions at both 
sides. The PDGF-BB protein has been expressed to the yeast surface and examined the 
function through YSD system and immunofluorescent labeling of c-myc tag by flow 
cytometry assay. In order to quantitatively and efficiently detect the florescent signal 
from the binding of aptamer to yeast cells by flow cytometry, the novel notion of 20-
bp biotinylated capturing oligo (B-CO) has been designed (Figure 2-1b). The design of 
B-CO is composed by a 20-mer oligo with 5’-biotin labeled, and the sequences of the 
20-mer oligo are complementary to the forward side of the constant regions on the 
aptamers. By taking the advantage of tetrameric streptavidin’s high affinity for biotin 
with a dissociation constant (Kd) on the order of ≈10
-14
 mol/L, the ratio adjustment for 
aptamer_B-CO hybrid coupled to strepavidin could be applied for various aptamers 
with different intensity of binding affinities. Through this approach, the strongest 
signal of florescent intensity can be observed by flow cytometry. The avidity 
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introduced by using the coupled streptavidin and B-CO_aptamer can increase the 
binding affinity of aptamers and stabilized the tetramerized structure. After annealing 
the B-CO to Pap1 during the aptamer refolding process, the Pap1_B-CO hybrid is 
ready to bind to the streptavidin that has been fluorescently labeled. At the same time, 
to estimate the dissociation constant (KD) of aptamers to antigens by flow cytometry, 
florescent intensities generated by serial diluted aptamer are collected to calculate the 
dissociation constant (Figure 2-1a). The preliminary result (Figure 2-1c) indicates that: 
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Figure2-1. Verification of cell-SELEX with yeast surface display system. (a) 
Dissociation constant (Kd) measurement from flow cytometry. The binding affinity of 
Pap1 measured by flow cytometry assay is 27.3 nM. The formula that calculated Kd 
equals to [ssDNA]1/2 Fluorescence(Max). (b) The design of biotinylated capturing oligo 
coupling to streptavidin-PE. (c) Binding of Pap1 and anti-c-myc/ anti-HA antibody to 
yeast before (shaded) and after (solid line) target protein expressed on the surface. 
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1) Pap1 shows concentration-dependent binding to yeast-surface expressed PDGF-
BB.  
2) Compared to the panel of antigen PDGF-AA and PDGF-BB, YSD system is an 
exquisite platform to express homologous proteins where specific aptamers can 
differentiate their target protein. 
3) Compared to the panel of antigen PDGF-BB and VEGF, YSD system is also a 
facile platform to express proteins that are structurally similar. I can examine the 
binding specificity of aptamer to its target protein in this way. 
4) To make the best use of flow cytometry results, a semi-quantitative way have been 
devised to rapidly estimate the affinity of an aptamers. After analysis, the 
dissociation constant of an aptamer can be calculated from collecting the data of 
serial-diluted samples by flow cytometry. 
 
Establish a novel platform for multiplexed-yeast-cell SELEX by using YSD to isolate 
specific aptamers. 
To conduct a pilot yeast-cell-SELEX with known aptamers, a spiked-in library 
that contains Pap1, VEGF165 Aptamer 7 (Vap7) [30]and random library in the molar 
ratio of 1:1:10
6
 with the complexity ~10
14
 has been made. The ssDNA library contains 
40 bp-variable region in the middle flanked by 20 bp-constant regions at both sides 
which also serve as primer binding sequences for PCR. (Library design: 5’-
TCCCACGCATTCTCCACATC-[40N]-CCTTTCTGTCCTTCCGTCAC-3’).  
The aptamer binding buffer (APBB, 10mM HEPES (pH=7.9), 125 mM NaCl, 25 
mM KCl, and 1 mM MgCl2) used throughout the whole selection to dissolve the 
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ssDNA library, perform the incubation of ssDNA library to yeast, and washing is the 
same. The flow of the pilot yeast-cell-SELEX is described shortly as followed (Figure 
2-2a). Before being incubated with target protein expressed yeast, the ssDNA library 
is heat-denatured at 95
o
C to form the secondary structure while the temperature 
gradually cools down. The secondary structure is critical for binding to target. 
Negative selection, the selection of ssDNA libraries with non-specific protein 
expressed yeast, is always performed at the initial step of every round of selection to 
get rid of non-specific binders, and is followed up by target-protein selection. After the 
incubation of library with target protein expressed yeast, appropriate washes are 
applied to get rid of the unbound ssDNA and heat-elution is performed to retrieve the 
bound ssDNA. The eluted ssDNA are then amplified by PCR for the subsequent round 
of selection and high-through-put sequencing. To amplify the retrieved ssDNA, 
forward and reverse primers are designed to prime the constant region for PCR 
reaction. The reverse primer is 5’-phosphorylated to generate the phosphorylated 
reverse strand. Lambda exonuclease is a highly processive 5’ to 3´ 
exodeoxyribonuclease that selectively digests the 5 -´phosphorylated strand of dsDNA. 
For this purpose, a 5 -´phosphate group is introduced into one strand of dsDNA by 
performing PCR where only one of the two primers is 5 -´phoshorylated. The 
phosphorylated strand is then removed by digestion with lambda exonuclease. The 
progress of selection and enrichment are monitored by flow cytometry. 
 
 
 
 34 
 
 
 35 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2. Characterization of Multiplexed-Yeast Cell SELEX. (a). Schematic flow of DNA 
aptamer selection using the yeast-cell SELEX. (b). Monitoring the progress of yeast-cell 
SELEX from R0 to R8. The histograms are showing detections of target screened libraries, 
known aptamers, and anti-c-myc antibody to yeast before (shaded) and after (thick lines) target 
protein expressed on the surface. (c). Binding test of newly selected aptamers of PDGF-BB to 
yeast before (shaded) and after (thick lines) target protein expressed on the surface. 
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In this experimental design, spike-in library is applied to PDGF-BB and 
VEGF165, and random library is performed in parallel with intercellular adhesion 
molecule 1 (ICAM-1) and ephrin B2 to validate yeast-cell-SELEX. Based on the result 
of progress of selection by flow cytometry assay (Figure 2-2b), PCR products from 
round4, round5, round7, and round9 are sequenced by performing high-throughput 
DNA sequencing technology with the Genome Analyzer II (Illumina). 
After the sequencing, the collected results are clustered and analyzed (Table 1); 
some of the top-ranked candidates are synthesized and tested for binding. The 
preliminary result indicates that: 
1) The top sequences from the PDGF-BB pool (Table 1) and VEGF165 pool (data 
not shown) are the spiked-in aptamers; this finding is revealed that spiked-aptamer 
can be enriched and fished through yeast-cell-SELEX. 
2) In addition to the spiked-in aptamers, some of the other aptamers also got enriched 
and isolated at later rounds of SELEX in the PDGF-BB pool. These aptamers 
(yPap1, yPap2, and yPap3) also showed binding of high affinity and specificity 
compared to the spiked-in Pap1 (Figure 2-2c). 
3) Interestingly, besides the spiked-in aptamer, these top-two-enriched aptamer 
(yPap1, yPap2) are identical or with high similarities to the top-two aptamers that 
have been previously published [29].  
4) The possible explanation for the failure of the rest of the three antigens could be 
that the yeast cell surface is negatively charged which contributes the repelling 
force to ssDNA that is also negatively charged. The likelihood of getting high-
affinity aptamers is thought to be related to the target protein’s isoelectric point 
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(pI). There is an inverse correlation between protein charge and aptamer Kd [33]. 
When a basic protein which usually has a high pI being incubated in APBB at 
pH=7.9, the protein net charge is reduced which considerably increases the affinity 
to be bound with ssDNA.  
5) Another possible explanation for the failure of the rest of the three antigens could 
be that the variety of the current ssDNA library is not complex enough. The 
ssDNA-library with longer variable region could be ideal to increase the 
complexity of the ssDNA library. 
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Table 2-1. Enriched aptamer sequences selected against PDGF-BB. 
 
 
     Reads of Each Cluster 
 
Name in 
the thesis 
Aptamer  
ID 
Sequences of selected aptamers (5'-->3') R4 R5 R7 R9 
 
yPap1 1 GATACTGAGCATCGTACATGATCCCGCAACGGGCAGTATT 3238 17430 49785 37270 
 
Pap1 2 ATAAGCTGAGCATCTTAGATCCCCGTCAAGGGCAGCGTAA 26605 22216 39303 30837 
 
yPap2 3 AGTTGAATGGTGTGGTCACTTCCAGTCCCGCAGGGCACAC 93 590 17679 2340 
 
yPap3 4 GATACTGAGCATCGTACATGATCCCGTCAAGGGCAGCGTAA 38 105 536 480 
 
 5 TGAGCATCTTAGATCCCGTCAAGGGCAGCGTAA 375 368 453 458 
 
 6 ATAAGCTGAGCATCTTAGATCCCGCAACGGGCAGTATT 13 85 645 365 
 
 7 ATAAGCTGAGCATCTTAGATCCCCGTCAAGGGGCAGCTA 98 110 759 219 
 
 8 ATAAGCTGAGCATCTTTAGATCCCTCAAGGGCAGCGTAA 82 112 207 148 
 
 9 AGTTGGTGTGGTCACTTCCAGTCCCGCAGGGCACAC 0 11 2507 142 
 
 10 AAGCTGAGCATCTTAGATCCCTGTCAGGGCAGCGTAA 72 110 216 142 
 
 11 GATACTGAGCATCTTAGATCCCCCAAGGGCAGCGTAA 25 29 170 135 
 
 12 ATAAGCGGAGCATCTTAGATCCCCGTCAGGGGCAGGGTAA 59 91 312 123 
 
 13 ACGAAGGTGGTTGCCCATGTCCTGCTAAGGGAATGTAAGT 0 9 2075 119 
 
 14 AAAAGCTGAGCATCTTAGATCCCCGTCATGGGCAGCGTAA 161 82 229 117 
 
 15 AACTGGGCATGGTACGATCATGTTAAGCCGGCTTCCCAGT 0 2 1483 72 
 
 
16 
CCATAAGCTGAGCATCTTAGATCCCCGTCAGGGGCAGCCTA
A 
10 34 109 55 
 
 17 ATAAGCTGAGCATCTTAGATCCCTGTCAAGGGGTAGCGAA 20 60 78 53 
 
 18 GCACTCTGGGGGTGGACGGGCCGGGT 192 61 16 49 
 
 
19 
ACATCGATACTGAGCATCGTACATGATCCCGCAACGGGCAG
TA 
4 17 50 43 
 
 20 ATAAGCTGAGCATCTTAGATCCCCGTCAAGGCCAGTGCAA 123 49 65 42 
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Discussion 
 
Here I demonstrate that our novel system, YSD-SELEX, is highly efficient in the 
discovery of high-affinity DNA aptamer binder. First of all, I established a new yeast-
cell-based assay for aptamer binding testing. I expressed PDGF-BB proteins to the 
surface of the yeast cells and synthesized the known DNA aptamers against PDGF-
BB[29]. To confirm the protein expression to the yeast surface, I tested the binding of 
either the HA tag or c-myc tag that are fusions to the protein of interest with 
antibodies and performed flow cytometry to evaluate the protein expression to the 
protein of interest. To fluorescently label the DNA aptamers, I designed a short DNA 
sequences, B-CO, that’s complementary to the forward side of the constant region 
from the DNA aptamer with a biotin labeled at its 5’-end, and mix with the DNA 
aptamer to 1:1 molar ratio during the aptamer refolding process to form the duplex. 
After the mixture of DNA aptamers and B-CO is generated, I applied the pre-formed 
complex with the same molar ratio of streptavidin-PE to fluorescently label the DNA 
aptamer for flow cytometry. By performing the binding test of using known DNA 
aptamer of PDGF-BB, I validated the YSD system can serve as a protein 
immobilization platform on yeast cells as a semi-quantitative way to rapidly estimate 
the affinity of an aptamers. 
To further utilize the YSD system for creating new aptamers, I conducted a pilot 
yeast-cell-SELEX with known aptamers, a spiked-in library that contains Pap1, 
Vap7[30] and random library in the molar ratio of 1:1:10
6
 with the complexity ~10
14
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has been made. The ssDNA library contains a 40 bp-variable region in the middle 
flanked by 20 bp-constant regions at both sides which also serve as primer binding 
sequences for PCR. (Library design: 5’-TCCCACGCATTCTCCACATC-[40N]-
CCTTTCTGTCCTTCCGTCAC-3’). I also developed the multiplexed-yeast-cell 
SELEX for aptamer selections by using the YSD system for PDGF-BB, VEGF-A, 
ICAM-I, and Ephrin-B2 in parallel. Taking advantage of next-generation-sequencing 
technology applied in this project, a thorough dataset from the sequencing result can 
be revealed to evaluate more candidates of aptamers (Table 2-1).  
The high similarity of the PDGF-BB aptamers selected from YSD-SELEX and 
microfluidic SELEX (M-SELEX) M-SELEX gives us a lot of room to tackle the 
reasons lead to the results. First of all, the starting materials of SELEX, the ssDNA 
library, could be the possible resource of creating identical aptamers from two 
different methods of aptamer selections. Both Cho et. al. [29] and our group ordered 
the ssDNA library with same length of variable region (40 nucleotides), and purchased 
from the same vendor (Integrated DNA Technologies). The theoretical complexity of 
the library (10
24
) is more comprehensive than the actual complexity for the 
experimental library (10
15), and it’s nearly impossible for a pipeline to generate two 
identical ssDNA libraries. However, I am not sure how the synthesis platforms from 
Integrated DNA Technologies had been automated and programmed that may generate 
two identical ssDNA libraries for the same length at two different time periods or if 
the vendor saved some aliquots from the original order of the Cho et. al. [29] and gave 
us an aliquot to complete our order. Secondly, the Craighead group from the aptamer 
community at Cornell University have experienced and proved selections that are done 
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with the same RNA library with the same sequences but with two different methods 
(traditional SELEX and RAPID-SELEX) could possibly enrich identical binders for 
the same target proteins (data not yet publish).  
The Yeast Surface Display system has been validated and established for a powerful 
and efficient platform for aptamer selections. YSD-SELEX will be the main focus for 
the following application derived from the validation in this chapter. After aptamers 
are obtained and well-characterized, these aptamers will be adapted into target-
activatable molecular probes of cancer imaging to enhance the contrast for in vivo 
diagnostic purpose. I expect these breakthroughs to accelerate current approaches of 
SELEX and facilitate molecular probes for cancer imaging. 
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CHAPTER 3 
 
 DISCOVERING APTAMERS BY CELL-SELEX AGAINST HUMAN 
SOLUBLE GROWTH FACTORS ECTOPICALLY EXPRESSED ON YEAST 
CELL SURFACE 
 
Summary 
 
3
SELEX, the process of selecting aptamers, is often hampered by the difficulty of 
preparing target molecules in their native forms and by a lack of a simple yet 
quantitative assay for monitoring enrichment and affinity of reactive aptamers. In this 
study, I sought to discover DNA aptamers against human serum markers for potential 
therapeutic and diagnostic applications. To circumvent soluble expression and 
immobilization for performing SELEX, I ectopically expressed soluble growth factors 
on the surface of yeast cells to enable cell-SELEX and devised a flow cytometry-based 
method to quantitatively monitor progressive enrichment of specific aptamers. High-
throughput sequencing of selected pools revealed that the emergence of highly 
enriched sequences concurred with the increase in the percentage of reactive aptamers 
shown by flow cytometry. Particularly, selected DNA aptamers against VEGF were 
specific and of high affinity (KD = ~ 1 nM), and demonstrated a potent inhibition of 
                                                 
3
 This chapter is modified with the permission of the publisher from Meng H, Pagano J, White B, 
Toyoda Y, Min I, Craighead H, Shalloway D, Lis J, and Jin M. Discovering aptamers by Cell-SELEX 
against human soluble growth factors ectopically expressed on yeast cell surface. (Submitted to PLOS 
ONE.) Hsien-Wei Meng designed the study, conducted the experiments, analyzed the data and wrote 
the paper. 
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capillary tube formation of endothelial cells, comparable to the effect of a clinically 
approved anti-VEGF antibody drug, bevacizumab. Considering the fact that many 
mammalian secretory proteins have been functionally expressed in yeast, the strategy 
of implementing cell-SELEX and quantitative binding assay can be extended to 
discover aptamers against a broad array of soluble antigens. 
 
Introduction and Significance 
 
Aptamers are specific DNA or RNA oligonucleotides selected from large random 
sequence pools for their ability to bind specific target molecules. Like antibodies, 
aptamers can bind with high affinity and specificity to targets ranging from proteins to 
small molecules [1-3]. Aptamers are obtained in vitro by a process called SELEX 
(Systematic Evolution of Ligands by EXponential enrichment [4-6] consisting of 
repeated rounds of negative selection and enrichment of nucleic acid binders against 
the molecules immobilized on membranes or beads. Selection of specific aptamers 
against cell surface proteins has also been performed using intact cells, a method 
termed cell-SELEX[7]. This method is particularly advantageous if the target 
molecules are cell surface or trans-membrane molecules not amenable to soluble 
expression and purification, and is necessary if aptamers are selected directly against 
surface markers specific to certain cell types.  
Growth factors, cytokines, and other soluble molecules present in the blood are 
important signalling molecules, mediating various functions in normal physiology [8] 
and are also implicated in the onset and progression of many diseases[9]. Antibodies 
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against serum proteins have been approved or are under investigation as therapeutic 
agents for various pathological conditions including cancer and inflammatory diseases 
[10-12]. More recently, aptamers as binding reagent have been developed against 
serum proteins with comparable affinity and specificity as antibodies [13]. To 
circumvent a difficulty with preparing antigens in solution to be used for selection of 
binding reagents, I have previously shown that mammalian cell surface molecules 
ectopically expressed on the surface of yeast cells provided a highly efficient platform 
for selection of specific, high-affinity antibodies [14]. Rapid discovery of specific 
antibodies was attributed to the fact that the molecules expressed in yeast cells as a 
fusion to a cell wall protein, agglutinin, are natively folded, and expressed at high 
density on cell surface. In addition, the complexity of other naturally expressed cell 
surface molecules would serve as competitive decoys for rapid depletion of non-
specific binders. Here I extend these strategies for antibody selection to the discovery 
of aptamers against human serum growth factors that are ectopically displayed on the 
surface of yeast cells using a standard cell-SELEX procedure.  
Among the soluble growth factors in serum, I have chosen VEGF, PDGF-A, and 
IL-6 as target antigens for selection of aptamers. VEGF and PDGF are the essential 
soluble factors for promoting vasculature growth, and antagonists of the family of 
growth factors or their receptors have been developed as drugs to treat several types of 
cancers[15]. Currently available VEGF antagonists exist at least in three different 
forms: as a monoclonal antibody (i.e., bevacizumab), as an RNA aptamer (i.e., 
pegaptanib[16]), and as a fusion of VEGF receptor (VEGFR) and the antibody Fc 
domain (i.e., VEGF-Trap [17] ). Currently, pegaptanib is the only FDA-approved 
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aptamer drug and is being used for treating age-related macular degeneration [18]. By 
ectopically expressing soluble proteins as cell surface molecules in yeast, I were able 
to use the cell-SELEX strategy to isolate specific DNA aptamers against VEGF and 
PDGF-A. Using high-throughput sequencing of selected pools generated during 
SELEX rounds, I isolated DNA aptamers against VEGF having higher binding affinity 
to VEGF in physiological buffer than previously reported DNA aptamers. By 
truncating full-length VEGF aptamers into shorter fragments containing all or a part of 
conserved structural motifs, I identified a minimal key structural motif for these 
aptamers. Various truncated aptamers against VEGF effectively blocked the capillary 
tube formation of endothelial cells, an assay used to gauge antagonist potency for 
blocking angiogenesis, comparable to the effect of the monoclonal antibody, 
bevacizumab.  
The procedure developed in this study can readily be adapted for the discovery of 
high affinity aptamers against a much larger set of targets by circumventing the 
challenge of functional expression, purification, and immobilization of mammalian 
soluble proteins. At the same time, flow cytometry-based assay for quantitative 
measurement of binding affinity and enrichment of reactive aptamers will aid rapid 
screening of highly enriched sequences revealed by high-throughput sequencing.   
 
Experimental Procedures 
 
Procedure for yeast cell-SELEX.  
An initial library of 10
15
 DNA aptamers was screened against yeast cells 
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expressing target proteins. Reactive aptamers against growth factors were dissociated 
from the cells by incubation with 10 mM DTT for 10 min at 25°C, which would 
reduce disulfide bonds between two subunits of agglutinin, thereby releasing Aga2 
and the bound aptamers from the cells. The mixture containing the aptamer complex 
was then cleaned up by a standard phenol-chloroform extraction and ethanol 
precipitation protocol [19], and amplified by PCR. The primer for the anti-sense 
strands to aptamers was phosphorylated at the 5’ end and was digested by lambda 
exonuclease (NEB) for 30 minutes at 37°C in 1X Lambda Exonuclease Reaction 
Buffer. To avoid chemical conjugation of aptamers with fluorescent dyes, I used 
phycoerythrin (PE)-conjugated streptavidin complexed with biotinylated 
oligonucleotides (which I call ‘capturing oligonucleotides’) complementary to the 
constant region of the aptamers. After 4-10 rounds of SELEX, the aptamer pools were 
subject to high-throughput next-generation sequencing for bioinformatics analysis (see 
below). 
 
Flow cytometry for detecting antigen expression and aptamer binding in yeast.  
Growth of yeast cells and induction of proteins was identical to the method 
described previously [20]. To verify the cell surface expression of target proteins, 5 μl 
of induced yeast culture was harvested, washed, and labelled at 30°C for 30 min with 
anti-c-Myc antibody 9E10 (ATCC), anti-HA antibody 3F10 (Roche Applied Science), 
or anti-VEGF antibody (R&D) as primary antibodies in labelling buffer (PBS, 0.5% 
bovine serum albumin (BSA), 10 mM MgCl2). After washing, cells were subsequently 
labelled at 4°C for 10 min with goat anti-mouse IgG-PE (Santa Cruz) or rabbit anti-
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goat IgG-PE (Santa Cruz) secondary antibodies in labelling buffer. Cells were washed 
with labelling buffer and re-suspended in 100 μl of labelling buffer and subjected to 
flow cytometry (Coulter Epics XL). To measure full-length aptamer binding to yeast, 
aptamers were first mixed with the B-CO complementary to either 5’ or 3’ constant 
regions, heated at 95°C for 5 minutes, and then gradually cooled down to room 
temperature for 20 minutes to form the duplex with B-CO at the forward site of 
constant region and the secondary structure of the aptamers. To measure the binding 
of truncated aptamers to yeast, truncated variants were synthesized with biotin 
attached at the 5’ end. Aptamers with capturing oligonucleotides or biotinylated 
aptamers were then complexed with PE-conjugated streptavidin at a molar ratio of 
aptamer to streptavidin at 1:1. After washing, yeast cells were incubated with 
aptamer/streptavidin complex in aptamer binding buffer (APBB; 10 mM HEPES, pH 
7.9, 125 mM NaCl, 25 mM KCl, and 1 mM MgCl2). After washing, cells were re-
suspended in 100 μl of labelling buffer and subjected to flow cytometry. The Hill 
equation was fit to data (mean fluorescence intensities vs. concentration of aptamers) 
using Prism 5 (GraphPad) to determine the equilibrium dissociation constants.  
 
Flow cytometry for measuring VEGF binding to HeLa cells.  
HeLa cells with the expression of VEGFR were used to measure the inhibition of 
VEGF binding to VEGFR by selected aptamers. Serially diluted VEGF (Syd Labs) 
was pre-incubated with the full-length hVap2 for 30 min at 4°C, and the mixture was 
then applied to HeLa. VEGF binding to HeLa was detected by anti-VEGF polyclonal 
antibodies (R&D) followed by a rabbit anti-goat IgG-PE-conjugated secondary 
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antibody (Santa Cruz). 
 
High-throughput DNA Sequencing.  
The aptamer pools after SELEX rounds of 0, 4, 8, and 10 were chosen and 
subjected to a high-throughput DNA sequencing. A small portion of the PCR products 
from each selected pool listed above were PCR amplified using the primers that 
contain a unique 9-mer barcode and the adapters necessary for the HiSeq 2000 
(Illumina) sequencing platform. High-throughput sequencing data derived from 
SELEX pools were filtered, clustered, and analyzed as previously described [21]. 
Processed sequences were analyzed separately for different selected pools, and those 
with >85% sequence identity were placed to the same clusters.  
 
Gel-shift assay with fluorescein-labeled aptamer.  
Aptamers were phosphorylated at the 5’ end with adenosine 5’-[γ-thio] 
triphosphate (Sigma-Aldrich), which were subsequently labelled with 5-
Iodoacetamidofluorescein (5-IAF) (Sigma-Aldrich), following a protocol previously 
described [22]. VEGF and DNA were mixed and incubated in binding buffer (10 mM 
HEPES, pH 7.9, 125 mM NaCl, 25 mM KCl, and 1 mM MgCl2) at room temperature 
for 2 hours, and were analyzed on a 5% polyacrylamide gel, run at 120 V in 1X 
tris/borate/EDTA (TBE) buffer at 4°C for 1-1.5 hours. The gel was then imaged by a 
phosphor-imager (Typhoon 9400 imager, GE Healthcare Life Sciences). The intensity 
of the bands were quantified by ImageJ (http://rsbweb.nih.gov/ij/, NIH), and the Hill 
equation was fit to data points to determine the equilibrium dissociation constant by 
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using Prism 5 (GraphPad). 
 
Human umbilical vein endothelial cell (HUVEC) capillary tube formation assay.  
Capillary tube formation assay was performed with a growth factor reduced 
Matrigel (BD Biosciences). After thawing overnight at 4°C, 50 μL Matrigel was 
placed into each well of a pre-chilled 96-well plate (Millipore), and the Matrigel was 
allowed to polymerize for 30 minutes in the 37°C incubator. HUVECs (Lonza) were 
placed in the wells coated with Matrigel at 2,000 cells per well in EGM-2 (EGM-2 
BulletKit; Lonza) containing 5% FBS. Cells were treated with antibodies 
(bevacizumab or isotope control) or aptamers used at 16.6 μM. After 6-12 hours of 
incubation, three randomly captured microscopic (Observer.Z1, Zeiss) images were 
recorded. Tube length was quantified by Angiogenesis Analyzer for ImageJ software 
(http://rsbweb.nih.gov/ij/, NIH). Tube length was assessed by drawing a line along 
each tube and measuring the length of the line in pixels. The average of three fields 
was taken as the mean value for each treatment. 
 
Results 
 
Cell-SELEX implemented by ectopic expression of human growth factors on yeast 
cell surface.  
DNA aptamers of 100 nucleotides (nt) in length were designed to contain a 60-nt 
variable region flanked by 20-nt constant regions, which serve as the primer annealing 
sites for PCR. The growth factors (PDGF-A, PDGF-B, VEGF, and IL-6) were 
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expressed as fusions to the cell wall protein agglutinin for cell surface presentation to 
enable cell-SELEX procedure (Figure 3-1a). A single round of SELEX consisted of 
negative selection of aptamers with yeast cells expressing unrelated proteins (PDGF-B 
or epidermal growth factor receptor), positive selection of specific aptamers that bind 
to target antigens, and PCR amplification. Double-stranded PCR products, composed 
of a 5’-OH sense strand and a 5’-phosphate anti-sense strand, were treated with 
lambda exonuclease to digest anti-sense strands and recover single-stranded aptamers 
[23]. The enrichment of aptamers specific to target antigens was confirmed by an 
increase in the percentage of binders measured by flow cytometry. In order to avoid 
direct labelling or chemical modification of aptamers for attaching fluorescent dyes, 
biotinylated oligonucleotides complementary to either 5’ or 3’ constant regions were 
used to form a complex with aptamers, which were then added to PE-conjugated 
streptavidin (Figure 3-1b). After eight to ten rounds of SELEX, a substantial (24-76%) 
sub-population of aptamers exhibited binding to PDGF-A and VEGF antigens (Figure 
3-1c). Considering the diversity of the initial library (10
15
), the enrichment factor for 
our cell-SELEX was estimated to be 100-fold per cycle. The percentage of reactive 
aptamers against IL-6 was lower, reaching ~12% at the final round.  
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Figure 3-1. Cell-SELEX procedure implemented by ectopic expression of human 
soluble growth factors on yeast cell surface. (a) A schematic drawing illustrates the 
procedure for cell-SELEX. Each round consists of subtractive panning, PCR 
amplification, and recovery of aptamer sequences by lambda exonuclease digestion. 
Human soluble growth factors were displayed on yeast cell surface as a fusion to 
agglutinin, composed of Aga1p and Aga2p subunits. Surface expression of the protein 
of interest was confirmed by antibody binding to hemagglutinin (HA) tag 
(YPYDVPDYA) and c-myc (EQKLISEEDL) tag. Enrichment and affinity of reactive 
aptamers to target molecules were quantified by flow cytometry. Selected aptamer 
pools were subjected to high throughput sequencing to isolate highly enriched 
sequences. (b) Aptamers for flow cytometry experiments were captured by 
biotinylated oligonucleotides complementary to either 5’ or 3’ constant regions. This 
DNA complex was mixed with PE-conjugated streptavidin at a 1:1 molar ratio. (c) 
Progressive enrichment of reactive aptamers against PDGF-A, VEGF, and IL-6 were 
confirmed by flow cytometry. Shown are the binding of aptamers to unrelated proteins 
(PDGF-B or EGFR) drawn in shaded histograms or to target proteins in open 
histograms. The percentage of subpopulations defined by arrows is shown for each 
histogram. Aptamers were used at 200 nM.  
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Discovery of specific aptamers in accordance with the degree of sequence multiplicity.  
Using sequence data obtained from the high-throughput sequencing, I calculated 
the multiplicity (the number of reads) of the sequences (after accounting for 
sequencing error by clustering) belonging to the different rounds of SELEX (Table 3-
1). I expected a correlation between multiplicity and affinity for aptamers, such that 
the aptamers with tighter binding to targets are more likely to possess higher 
multiplicity [24]. I chose for high-throughput sequencing analysis the pools prior to 
SELEX (round 0) and after rounds 4, 8, 9, and 10; the selected pools from the last 
three rounds were included as there was a substantial increase in reactive binders 
measured by flow cytometry (Figure 3-1c). Highly enriched sequences were also 
tested individually for binding to respective targets by flow cytometry using 
biotinylated oligonucleotides complementary to the 5’ end and PE-conjugated 
streptavidin (Figure 3-2). For PDGF-A, the top 10 ranked sequences at round 10 
accounted for 63% of the total reads with a gradual decrease in multiplicity from top 
to bottom. In contrast, the top 2 sequences at rounds 8 to 10 for VEGF (named 
‘hVap1’ and ‘hVap2’) accounted for 80% of the reads, with a dramatic decrease in 
multiplicity for the remaining sequences. Notably, the gradual decrease in the level of 
binding for the top three PDGF-A aptamers (named ‘hPAap1’ to ‘hPAap3’) (Figure 3-
2) was correlated with multiplicity, emphasizing quantitative nature of our flow 
cytometry-based binding assay.  
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Figure 3-2. Confirmation of binding specificity of the top-ranked aptamers identified 
by sequence multiplicity. Highly enriched aptamer sequences were identified by high-
throughput sequencing analysis, and tested by flow cytometry for specificity and 
binding affinity to respective targets. The binding of individual aptamers to respective 
target is shown as open histograms drawn in thick line, to unrelated protein as open 
histograms in thin line, and to uninduced yeast cells as closed histograms. The 
percentage of subpopulations defined by arrows is shown for each histogram. 
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Table 3-1. Enriched aptamer sequences selected against target molecules 
   Percentage of Total Reads 
Target Aptamer ID Sequences of selected aptamers (5'-->3') R4 R8 R9 R10 
PDGF-A 1 CAGAGCAGGGCGCCGTGTCGCATAGTGTTGTCACTCCCCTGGAGGTCCATGCGAAATATG 0.00 13.66 18.52 12.41 
2 GCGGTATTACCGGGGGCCCTCCGGGTACGATTGGGGCTTCCCTATGCGGATCAGTTGGTA 0.00 7.38 11.00 7.40 
3 CGCCTCTTCTCACCGTGTGAGACTCCACGTCTTGATTGCAGGGTGGTTGCTTCCCATGCG 0.00 1.71 1.57 6.85 
4 GTCGCCAAGGGCCGGGCACTGTCTACCGGTATGGTTTAACCTCCCACGCATAGATCGCGT 0.00 3.14 6.36 6.79 
5 GCTAGGGCCGTCAGGCATAGAACCGTCTATTCAACAGAGGATTCTCCCAGATTCGGTGCG 0.00 15.11 10.02 6.64 
6 GAAACGCCGCTGGGCTAACGGGGGGCCCACAGCGTGGGGACGGTGTTTTGATCTATTCTA 0.00 5.49 11.16 5.64 
7 CTCTGGTCGTGAGCTGGGCGGCTATTGCGTGCTAGCCGGTTACTTTTAGTCCCTAATGCG 0.00 2.94 3.50 5.52 
8 GCGTACGTCTCTCTTCAAGACATGCGGACGGGGGCCCGGTACTACGGGGACGATGTTGCG 0.00 3.78 4.88 5.38 
9 GCTGTGGCACACAGGGGGCCCGCAGGTTTTGCAGCGGGGACGATTACTTTTTCGTGCAG 0.00 20.62 12.00 3.47 
10 AAGTTGTCAGGGCAGGTCGGTTGGGCCAACTTGCATGAGTCATGCTTTCCCCGGCGCTCT 0.00 1.36 2.06 3.24 
VEGF 1 TAGCCCACTGCATAGAGGTAGCCACGTATGTGGGTGTTACCCATTCGTAGCTACCGGTGA 0.01 79.91 58.21 31.70 
2 AAAGCCCACTGCATAGAGGCCGCTCAACATGCGAGCCGGTGTACTTCAACAGGTATCCT 0.00 2.60 15.81 48.94 
3 GTGGCTCCGCCCACTGCAAAGAGATGGGGGTATCTTCCATCAGTACCATCATCGGTGTAT 0.00 0.17 1.12 4.18 
4 AATCCCTGGGCGTGCAGCCCCTATTGCGTGCTGCCCACTGCAAAGAACGATAGTGGTGTC 0.00 0.32 1.81 4.14 
5 AGGGTCTTCAGAATTGCTTGGGTCCCCACTGGATAGAGCACAAACTGGGCGGTGCATGAC 0.00 12.80 21.07 4.12 
6 CGGAGATAAGTTAGCCCACTGCAGAGAGGCTCTAGTTTGGCATGCCGTCAAGCCGTTGTT 0.00 0.15 0.77 2.26 
7 ATACGTTGGATCCCACTGAATAGAATTTCGCAGCCTGCTCGAACTGGTGTCGCTAATGTT 0.00 0.06 0.23 0.86 
8 CTTAGTCTACCTAAAACAGCCCACTGCATAGAATCTCGGCTTGTACGAGATGGTTGAACA 0.00 0.01 0.02 0.19 
9 TCTTTCGTGTATAATGGCCCACTGCATAGAGTGACTTGTCATGGTGTTTCCATACTTGGT 0.00 0.01 0.01 0.16 
10 TCCCCACTGGTAAGAGCTTGACAAAGCGGTGTTGTTTCATCTCAGTCTTAACTCTGAGTC 0.00 0.01 0.01 0.02 
IL-6 1 TCCCACGCATTCTGCACATCGATACTGAGCATCGTACATGATCCCGCAACGGGCAGTATT 0.00  0.03 0.05 
2 TCCCACGCATTCTGCACATCGCGGTTGGGGGGTAAGTGGGGGGTGGTCAGGGGAGGCGG 0.00  0.01 0.02 
3 TCCCACGCATTCTGCACATCCGGTTTTTGCTCCCATAGTGGACCCTATGTCGGCCCATA 0.00  0.01 0.02 
4 TCCCACGCATTCTGCACATCCTGGCTGCCTCCTAACGCGATCTACTGTTCCAATAGCCAC 0.00  0.01 0.01 
5 TAGCCCACTGCATAGAGGTAGCCACGTATGTGGGTGTTACCCATTCGTAGCTACCGGTGA 0.00  0.03 0.01 
Underlined sequences correspond to the conserved sequence motif. Sequences were ranked in the order of highest to lowest percentage of total reads of 
R10 pools, except the top two sequences in VEGF.  
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Identification and characterization of aptamers for VEGF.  
I then analyzed the highly enriched sequences for the presence of conserved or 
shared primary (consensus motif) and secondary structures. The top 10 aptamers in 
round 10 against VEGF were found to contain the consensus motif of 
[G/C]CCCACTGCA[T/A]AGAG folded into a stem-loop (Figure 3-3a and b), 
although the position of this motif differed within the variable region (Table 3-1). In 
contrast, no obvious consensus motifs were found for the PDGF-A aptamers that were 
present in the majority of the top ranked sequences. As anticipated from the lack of 
appreciable binding to IL-6 (the binding of the top-ranked aptamer to IL-6 is shown in 
Figure 3-2), none of the sequences selected against IL-6 reached a multiplicity of 0.1% 
(Table 3-1). The failure to isolate aptamers against IL-6 is likely due to the lack of 
high affinity sequences in our starting library, which contained 10
15
 sequences out of a 
possible diversity of 4
60
 ~ 10
36
 for the 60-nt variable region, as well as the nature of 
IL-6 (isoelectric point (pI) 6.2 compared to 9.5 for PDGF-A and 7.6 for VEGF) being 
less ‘aptogeneic’ to nucleic acid aptamers. 
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Figure 3-3. Determining consensus motif, secondary structure, and solution affinity of 
the aptamers against VEGF. (a) The consensus motif shared among the top ten highly 
enriched sequences against VEGF was identified using the MEME Suite 
(http://meme.nbcr.net/meme/). (b) Shown are the secondary structures of the 60-nt 
variable region of the top two aptamers, hVap1 and hVap2, predicted by Mfold 
(http://mfold.rna.albany.edu/). (c-d) Solution affinity (KD) of the full-length hVap1 
and hVap2 against VEGF was determined by F-EMSA (c), and by fitting the Hill 
equation to the data (d). VEGF was used at a series of 2/3-fold serial dilutions starting 
at 53 nM, while labeled aptamers were used at 500 pM. 
 
 
 
 62 
I then chose the top two ranked aptamers against VEGF to further define solution 
affinity, structural motif, and their potency as VEGF antagonists. The level of binding 
to VEGF by hVaps captured by the oligonucleotides complementary to either side of 
the constant region was equivalent (Supplementary Figure S1), implying that the 20-nt 
constant region is not a part of the active structure and that the variable region alone is 
responsible for binding to VEGF. To quantitatively measure the solution affinity of 
aptamers, I performed a fluorescence electrophoretic mobility shift assay (F-EMSA) 
using fluorescently-labeled VEGF aptamers [22]. The affinity (equilibrium 
dissociation constant) of hVap1 and hVap2 against VEGF was measured, respectively, 
to be KD = 1.4 ± 0.1 nM and 1.9 ± 0.2 nM (Figure 3-3c and d). In comparison, 
previously reported DNA aptamers against VEGF bound with much weaker affinity 
by F-EMSA (KD = 107.4 ± 9.6 nM for SL12 [25]) or did not exhibit measurable 
binding (the 25-nt DNA aptamer by Potty et. al., [26]) by flow cytometry when tested 
under equivalent physiological buffer conditions (Supplementary Figure S2). Both 
hVap1 and hVap2 were predicted to have the same stem-loop structure comprised of 
the consensus motif, followed by a longer stem-loop (Figure 3-3b). To further 
determine if the consensus motif and the predicted secondary structure (Figure 3-3a 
and b) are the required elements for binding to VEGF, I truncated full-length aptamers 
into several variants, containing the first stem-loop of the consensus motif and a 
portion of the adjacent stem-loop (Figure 3-4a and Table 3-2). Again, I performed F-
EMSA for each hVap variant and determined the KD to be 1.7 ± 0.1 nM for 
hVap1_T1979, 2.5 ± 0.2 nM for hVap1_SST, 5.6 ± 0.3 nM for hVap1_STEM, and 
107.4 ± 9.6 nM for hVap2_T2160 (Figure 3-4b and c). Equilibrium dissociation 
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constants determined by F-EMSA were in close agreement with those estimated from 
flow cytometry experiments (Supplementary Figure S3), emphasizing simple yet 
quantitative nature of our assay. 
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Figure 3-4. Identification of structural motifs of anti-VEGF aptamers. (a) Full-length 
anti-VEGF aptamers were shortened to contain the first stem-loop containing the 
consensus motif shared among all highly sequenced aptamers and a part of the longer 
stem-loop. (b-c) The binding affinities of all four truncated aptamers were determined 
by F-EMSA assay (b) and by curve-fitting of the Hill equation to the data (c). VEGF 
was used at a series of 2/3-fold dilutions starting from 500 nM, and labeled aptamers 
were at 600 pM. 
 
 
 65 
It appears that the first stem-loop in hVap1 is the key structure for binding to 
VEGF as a significant portion of the second stem-loop could be truncated, applied to 
hVap1_STEM and hVap1_SST, with less than a 4-fold reduction in binding affinity. 
Although full-length hVap2 was equally competent as hVap1 in binding VEGF, 
hVap2_T2160 (hVap2 without a possible third stem-loop (Figure 3-3b)) bound VEGF 
with ~50-fold reduction in affinity. It is worth mentioning that the 32-nt hVap1_SST, 
about half the size of hVap1, bound VEGF with a minimum loss in affinity.  
 
 
Table 3-2. Nucleotide sequences of truncated hVaps 
Aptamer Name Sequences of truncated aptamers (5'->3') Length 
(nt) 
hVap1_T1979 TCTAGCCCACTGCATAGAGGTAGCCACGTATGTGGGTGTTACCCATTCGTAGCTACCGGTG 61 
hVap1_Stem TCTAGCCCACTGCATAGAGGTAGCCACGTATGT-------------TCGTGGCTACCGGTG 48 
hVap1_SST TCTAGCCCACTGCATAGAGGTAGC-----------------------------TACCGGTG 32 
hVap2_T2160 AAAGCCCACTGCATAGAGGCCGCTCAACATGCGAGCCGGT 40 
Dashed lines correspond to the nucleotides that were removed from hVaps. Truncated variants of hVap1 contains 2 
nucleotides belonging to the 5’ constant region to provide structural flexibility to the variable region when bound with 
streptavidin. hVap1_Stem contains the first and second stem-loops without the third stem-loop inserted into the second 
stem-loop. hVap1_SST contains the second stem-loop that is greatly shortened. hVap2_T2160 contains nucleotides 21-60 
of the full-length 100-nt hVap2.  
 
 
Aptamers bind the heparin-binding domain in VEGF.  
VEGF is a major regulator of physiological and pathological angiogenesis [27]. 
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VEGF-A or VEGF itself exists in at least seven homodimeric isoforms, of which 
VEGF165 (the isoform referred to as VEGF herein) is the dominant species, 
containing both the receptor-binding domain present in all isoforms of VEGF and a 
heparin-binding domain (HBD) [27]. HBD has been shown to enhance VEGF binding 
to VEGFR through its interaction with cell-associated heparin-like 
glycosaminoglycans and sequestration through extracellular heparin molecules [28]. 
Pegaptanib is known to recognize the HBD in VEGF, and is likely to inhibit VEGF 
binding to VEGFR-2 in cells [16]. I examined if our aptamers against VEGF could be 
used as antagonists to VEGF-mediated signalling. With an increasing concentration of 
hVap2 pre-incubated with soluble VEGF, I observed a gradual decrease in the level of 
VEGF binding to HeLa cells known to express receptors for VEGF (Figure 3-5a). To 
further define the structural basis of the inhibition of VEGF binding to VEGFR by our 
aptamers, I tested if the aptamer binding site is in the receptor binding site or in HBD. 
When aptamers were tested for binding to VEGF110, devoid of the HBD of VEGF165, 
all truncated versions of aptamers completely lost the ability to bind VEGF (Figure 3-
5b), indicating that the epitope for our aptamers is also within the HBD. However, the 
preformed complex of VEGF with truncated aptamers, except with hVap2_T2160, 
could not be reduced by the addition of soluble heparin molecules presumably due to 
tighter binding of VEGF with the aptamers than with heparin. The decrease in 
hVap2_T2160 binding to VEGF by heparin is ascribed to its lower affinity binding 
(KD = 107 nM). HBDs in human and mouse VEGF are highly conserved (50 identical 
out of 55 amino acids, shown in Figure 3-5c), which explains the cross-reaction of 
hVaps with mouse VEGF (Figure 3-5d).  
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Figure 3-5. Selected aptamers bind the HBD in VEGF. (a) The potency of anti-VEGF 
aptamers for the inhibition of VEGF binding to VEGFR was measured as the percent 
inhibition of VEGF binding to VEGFR-expressing HeLa cells. VEGF at 250 nM was 
pre-incubated with hVap2 at 0 - 250 nM. VEGF binding to cells was detected by 
polyclonal anti-VEGF antibody. (b) Anti-VEGF aptamers were tested for binding to 
yeast cells expressing VEGF165 or VEGF110 lacking in HBD with or without post-
incubation with 100 nM heparin. Heparin was used to compete with the aptamers for 
binding to VEGF. VEGF expression was confirmed by polyclonal anti-VEGF 
antibody. Truncated aptamers were biotinylated at the 5’ end to form a complex with 
PE-conjugated streptavidin. (c) Sequence alignment of human (H) and murine (M) 
VEGF. ‘*’ indicates identical amino acids between human murine VEGF. Receptor 
binding domain (residues 1-110 for human VEGF) and heparin binding domain 
(residues 111-165 for human VEGF) are denoted. (d) Comparison of the level of 
binding of hVap1 and hVap2 to human (shown in thick open histograms) and murine 
VEGF (shown in thin open histograms). Aptamer binding to uninduced yeast cells is 
shown in filled histograms. Aptamers were bound with the biotinylated 
oligonucleotides complementary to the 5’ constant region to form a complex with PE-
conjugated streptavidin. 
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hVaps potently inhibit capillary tube formation of endothelial cells.  
Next, using an endothelial capillary tube formation assay, I examined the potency 
of selected VEGF aptamers for their inhibition of VEGF-mediated endothelial vessel 
formation. Tube formation assay is a well-defined in vitro assay that has widely been 
used to screen for angiogenic and anti-angiogenic factors [29], as it reciprocates the 
process of physiological angiogenesis. HUVECs plated at sub-confluent densities 
developed complex mesh-like structure patterns when cultured without antagonists, 
control antibodies, or control ssDNA (Figure 3-6). When treated with bevacizumab 
(16.6 μM), the HUVECs formed discontinuous but visible sprouting capillary tube 
patterns. Remarkably, the inhibitory effect of hVaps was more potent with little 
capillary sprouting patterns, resulting in a reduction of tube length by 60-80% over 
controls (Figure 3-6b). Therefore, I conclude that our newly selected VEGF aptamers 
may possess a therapeutic potential for diseases that can be treated or alleviated by 
anti-angiogenesis therapy. 
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Figure 3-6. Anti-VEGF aptamers antagonize angiogenesis. Antagonistic potency of 
anti-VEGF aptamers was measured by a capillary tube formation assay using 
HUVECs embeded in Matrigel. (a) Shown are the representative images of HUVECs 
forming capillary tubes after HUVECs were cultured in the presence of anti-VEGF 
aptamers, bevacizumab, and various controls. Scale bar = 100 μm. (b) Total tube 
length within a randomly chosen microscopic field (25x magnification) was quantified 
by Angiogenesis Analyzer for ImageJ software. Bar graph shows the mean and 
standard deviation of the measured total tube length (n = 3). 
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Discussion 
 
Serum growth factors are important therapeutic and diagnostic targets, and 
peptides, antibodies and more recently aptamers have been developed that can detect 
and antagonize the roles mediated by these growth factors. However, it is challenging 
to functionally express and immobilize these soluble molecules and to maintain their 
native conformation through repeated rounds of in vitro selection. Furthermore, 
conventional methods for determining binding affinity and specificity of candidate 
aptamers are tedious and incompatible with rapid screening of highly enriched 
sequences identified by high-throughput sequencing analysis. To address these 
limitations, I developed a new cell-SELEX approach that circumvents the need for 
soluble expression, purification, and immobilization of target molecules, and is well-
suited for quantitative and rapid screening of candidate aptamers. This is implemented 
by ectopic expression of soluble growth factors on the cell surface of yeast, and flow 
cytometry-based assay to quantify binding affinity and specificity of reactive aptamers. 
The aptamers selected against VEGF using this approach were found to possess high 
affinity and selectivity, and blocked endothelial tube formation as potently as the 
monoclonal antibody drug, bevacizumab. Although a number of DNA aptamers 
against VEGF have been reported, the fact that the aptamers selected in this study are 
the only high affinity DNA binders in physiological buffer conditions underscore the 
efficiency of our SELEX strategy.  
Compared to the proteins immobilized to planar membranes or polymer beads, 
the proteins expressed on the yeast cell surface provide an optimal condition for 
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rapidly depleting non-specific binders and enriching for high affinity binders. This is 
due to the fact that the library undergoes negative selection with all natively expressed 
yeast proteins and the positive selection is specific to target protein. Proteins displayed 
on the surface of yeast cells via a fusion to agglutinin are natively folded, as required 
to be released through a secretory pathways rather than being degraded intra-cellularly 
[30]. Furthermore, surface expression of target proteins in living cells should prevent 
the targets to be non-uniformly displayed to the extent that leads to local clustering or 
aggregation. This has been recognized as a potential problem as targets immobilized 
onto planar membranes or beads are prone to selecting non-specific aptamers due to 
their binding to multiple targets in a cooperative manner [31]. Finally, the net negative 
charge of the yeast cell wall, composed primarily of polysaccharides, creates a 
stringent interaction environment for negatively charged nucleic acid aptamers and 
proteins present on cell surfaces. These conditions are likely responsible for the 
successful discovery of aptamers against VEGF and PDGF-A as specific and high 
affinity binders.  
High-throughput sequencing analysis of different aptamer pools revealed a 
quantitative correlation between aptamer multiplicity and binding affinity. Candidate 
aptamers against VEGF are dominated by the top two ranked aptamers, hVap1 and 
hVap2, accounting for 80% of the total reads starting from the 8th round SELEX pool. 
These two aptamers were confirmed to be high affinity binders to VEGF and potent 
antagonists to VEGF-mediated angiogenesis. Although the 7th round pool was not 
subjected to high-throughput sequencing, a dramatic increase in the percentage of 
reactive aptamers from the 7th to the 8th round pool implied that at least 8 rounds of 
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SELEX were necessary for the discovery of the high affinity aptamers. This 
corresponds to an enrichment factor of 100-fold per cycle, because the diversity of the 
starting library is 10
15
. It is also interesting to note that while hVap1 was dominant 
from the 8th round, hVap2 progressively enriched from the 8th to the 10th round of 
SELEX. In contrast, the less pronounced shift of the flow cytometry histogram peaks 
suggests that aptamers against PDGF-A are weaker binders (with KD ~ 10-100 nM), 
which is also reflected in the lack of dominant species revealed by sequence 
multiplicity. The power of large-scale sequencing for aptamer discovery is also 
apparent in aptamer pools selected against IL-6. Although flow cytometry revealed 
gradual enrichment of a reactive population at the 10th round, no single aptamer 
accounted for more than 1% of the total reads.  
The top ranked aptamers by sequence multiplicity accounting for more than 95% 
reads were found to share the same consensus motif of 15 bases, which adopted a 
short hairpin structure. Variants of the full-length VEGF aptamers, containing the 
consensus motif and a truncated form of the adjacent stem-loop, were found to retain 
almost full capacity binding to VEGF. I speculate that the stem-loop adjacent to the 
consensus motif may affect binding to VEGF either by direct contact with VEGF or 
influencing the structure of the consensus motif. The shortest version of the 32-nt 
VEGF aptamer, consisting of the consensus motif and an adjacent short stem-loop 
structure, retained affinity to VEGF with less than 2-fold reduction from the full-
length 60 nt aptamers. Furthermore, in an endothelial capillary tube formation assay 
these shortened versions were as potent as the full-length aptamers, which themselves 
were equally or more effective than the anti-VEGF monoclonal antibody, 
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bevacizumab. Therefore, the VEGF aptamers developed in this study may find a 
therapeutic use in diseases whose progression is critically dependent on VEGF-
mediated vasculature growth. 
Affinity measurement by F-EMSA and flow cytometry demonstrated that the 
aptamers discovered in this study had higher affinity (KD < 10 nM) relative to two 
previously isolated DNA aptamers: 1) SL12, a truncated version of the original 66-nt 
aptamer that was measured to have KD = 130 nM and 2) the 25-nt aptamer by Potty et. 
al., which bound VEGF at a lower affinity with increasing salt concentrations, 
approaching a μM KD at physiological conditions. Unlike the reported KD value of 5 
nM for SL12, which was determined by surface plasmon resonance [25], the affinity 
estimated by our F-EMSA assay was ~100 nM, closer to the affinity of the full-length 
66-nt aptamer [32]. The binding of the 25-nt aptamer by Potty et. al. [26] could not be 
detected by flow cytometry performed under physiological buffer conditions, likely 
because the detection limit of our assay is KD ~ 1 μM. Although all these DNA 
aptamers and the RNA aptamer (pegaptanib) bound VEGF with a wide-range of 
affinity (sub-nanomolar to micromolar KD), they all target the HBD, which has a pI of 
9 and tends to be a dominant site for interaction with aptamers. One may need to use 
VEGF devoid of the HBD, such as VEGF110, to isolate aptamers that bind the 
receptor binding domain to isolate aptamers that can antagonize all isoforms of VEGF.   
Overall, the strategy developed in this study, enabling cell-SELEX for selecting 
aptamers against soluble proteins, rapid enrichment of high affinity and specific 
binders, and quantitative monitoring of progressive enrichment can be readily 
extended to the discovery of aptamers against a larger set of antigens. For example, 
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this can be implemented with multi-well plates and automated fluid-handling systems. 
The fact that quantitative estimation of the binding affinity between aptamers and 
target proteins can be achieved by flow cytometry has a significant advantage over 
conventional methods such as EMSA, which require purified proteins and labelled 
nucleic acids. Flow cytometry allows a set of yeast cells expressing hundreds of 
different target proteins to be tested for binding to multiple candidates. Thus, our cell-
SELEX platform can facilitate the discovery of high affinity aptamers against a large 
set of soluble proteins.  
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SUPPLEMENTARY MATERIALS 
 
 
Figure S 1. Constant regions are not part of the active conformation of aptamers. Flow 
cytometry data are generated with hVap1 (A) and hVap2 (B) aptamers captured with 
biotinylated oligonucleotides complementary to either 5’ (5’B-CO) or 3’ constant 
regions (3’B-CO). The concentration of aptamers used for labeling yeast is indicated 
for each histogram. Aptamer binding to yeast cells expressing VEGF is shown in open 
histogram and to uninduced yeast in filled histogram.  
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Figure S 2. Binding affinity measurement of previously reported VEGF aptamers. (a) 
F-EMSA of DNA aptamer SL12 [25] was performed to examine its binding affinity in 
solution. SL12 was labeled at the 5’-end with fluorescein, used at 500 pM. VEGF was 
used at a series of 2/3 dilutions ranging from 0 to 1,360 nM. The fraction-bound 
values were used to determine the dissociation constant (KD) of SL12 by the Hill 
equation. (b) Flow cytometry measurement of the binding of the 25-nt aptamer by 
Potty et. al. to yeast cells expressing VEGF (open histogram) and to uninduced yeast 
cells (open histogram). The aptamer used at 200 nM for binding was biotinylated at 
the 5’ end to form a complex with PE-conjugated streptavidin. 
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Figure S 3. Measuring binding affinity of truncated aptamers to VEGF by flow 
cytometry. Aptamers were used at 0 – 100 nM. Data points are mean ± standard 
deviation from duplicate experiments. 
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Figure S 4. The primer set of selected pools for high-throughput DNA sequencing by 
the HiSeq 2000 (Illumina). (a) Primer set; forward primers: with adaptors to the 
flowcell and to the DNA, barcodes for each chosen-selected pools; reverse primer: 
with adaptors to the flowcell and to the DNA. (b) Both forward and reverse primers 
are further sequences for the adaptors to the flowcell. (c) Each barcode was subjected 
to a selected pool to differentiate. I first took a small portion of selected DNA pools 
and performed PCR with primers in (a). After clean-up, I then performed PCR with 
the primer set in (b). 
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CHAPTER 4 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
Conclusions 
 
I have developed a yeast-cell-based technology for the efficient selection of nucleic 
acid aptamers for multiple targets in parallel. Our yeast-cell SELEX has a number of 
advantages over other methods of SELEX processes. First, our yeast-cell SELEX system 
utilized the advantage of yeast surface display to mobilized target proteins at the yeast 
cell surface. This character greatly simplified the protein purification steps compared to 
other methods of SELEX. The platform of yeast surface display expresses proteins 
through endoplasmic reticulum (ER) with proper protein folding and modifications that 
unfolded proteins be retained in the reticulum. Second, yeast-cell SELEX also offers a 
great advantage with east to monitor the selection enrichment and progression throughout 
the entire SELEX. By examining the binding events between yeast targets and selected 
pools through flow cytometry, data set can be facile to generate and analyze the 
enrichments and progressions of selected pools during SELEX. Last but not the least, the 
yeast surface is negatively charged, and the aptamer pools (DNA or RNA) are also 
negatively charged. The aptamers that got enriched and selected from yeast-cell SELEX 
are usually with very tight binding affinity maybe due to these aptamers having 
conquered the natural repelling force caused by the interaction of yeast cell surface and 
the aptamer pool.  
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For this study, I focused on the selection of DNA aptamers; however, our approach 
would also work for RNA aptamers. I sought to discover DNA aptamers against human 
serum markers for potential therapeutic and diagnostic applications. To circumvent 
soluble expression and immobilization for performing SELEX, I ectopically expressed 
soluble growth factors on the surface of yeast cells to enable cell-SELEX and devised a 
flow cytometry-based method to quantitatively monitor progressive enrichment of 
specific aptamers. By applying high-throughput sequencing of selected pools, I revealed 
that the emergence of highly enriched sequences concurred with the increase in the 
percentage of reactive aptamers shown by flow cytometry. Particularly, selected DNA 
aptamers against VEGF were specific and of high affinity (KD = ~ 1 nM), and 
demonstrated a potent inhibition of capillary tube formation of endothelial cells, 
comparable to the effect of a clinically approved anti-VEGF antibody drug, bevacizumab. 
Considering the fact that many mammalian secretory proteins have been functionally 
expressed in yeast, the strategy of implementing cell-SELEX and quantitative binding 
assay can be extended to discover aptamers against a broad array of soluble antigens. 
 
Future Directions 
 
Since the fact that many mammalian secretory proteins can be functionally 
expressed in yeast, the strategy of expanding and implementing cell-SELEX and 
quantitative binding assay can be extended to discover aptamers against a broad array of 
soluble antigens. In order to reach this goal, I will further carry out a comprehensive 
design of experiments to conduct yeast-cell SELEX systematically in a 96-well or 386-
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well plate. The advantage here is that yeast-cell SELEX provides a panel of aptamers 
with diverse characteristic with regards to their interactions with several different kinds 
of proteins not just with soluble ones. Afterwards, a potentially constitutive biomarker 
library for disease treatment, detections and diagnosis can be established. 
After specific aptamers have been identified, Surface Plasmon Resonance based 
Biacore will be applied to validate each aptamer’s binding affinity and specificity. 
Necessary affinity maturations will be issued to some aptamers to increase their affinity, 
but affinity maturation is not required if there are aptamers with high affinity. 
 
Aptamer as imaging probes. 
One of the ongoing and interesting designs of applications for the generated library 
is aptamer-conjugated moieties as molecular probes for tumor imaging. Tumor imaging is 
to identify tumor properties and growth, and in a long run, to monitor treatment and treat 
the tumor. Molecular imaging (MI) has made a significant impact on the field of 
oncology and is playing an increasingly important role in the diagnosis and treatment of 
cancer, through clinical applications, research and drug development. Conventional 
molecular probes typically require a waiting period of hours following injection to allow 
the probe to distribute to target tissues and for excess probe to exit the body before an 
imaging procedure. Despite that washout period, low levels of unbound probe remain in 
the body during the imaging procedure and decrease contrast and sensitivity[1]. To 
improve contrast, molecules such as antibodies and peptides have been engineered to 
activate via enzyme processing upon target binding to produce a signal[2]. However, 
these molecules need to undergo a series of modifications to decrease immunogenicity; 
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antibodies also are bulky molecules that take time to clear from the body[3] though 
conformational changed aptamers upon binding to their target have been designed[4]. 
To synthesize and design an aptamer probe for imaging, a thorough understanding 
of aptamer binding motif is needed. For imaging purpose, a targeted binding moiety can 
be designed. Carriers suitable for multimodality including both imaging and therapeutic 
intervention, include protein scaffolds, specifically streptavidin and avidin, which have 
been approved for clinical trial, and demonstrate superior diffusion through interstitial 
space compared to that of rigid spherical particles of comparable size. To synthesize a 
multi-versatile activatable aptamer-conjugated moiety, taking the advantage of four 
binding sites to biotinylated molecules of a tetrameric streptavidin molecule will be an 
efficient design. The primary goal of the design is to utilize the incorporation of aptamer 
probe and streptavidin to stabilize the whole complex and prevent degradation during 
manipulations. Furthermore, the complex can increase the avidity of aptamer probes to 
target, and streptavidin can be fluorescently labeled if the labeling site at the aptamer is 
not ideal. Ultimately, four different binding sites of a streptavidin can be loaded not just 
with aptamer probes but also with different payloads for further applications.  
 
Aptamer as therapeutics 
Aptamers can be selected from libraries of random sequence oligonucleotides to 
bind a various range of proteins with affinities and specificities that are comparable to 
antibodies. Unlike antibodies, aptamers are easier to be created, less immunogenic, and 
more economical to synthesize. Despite these advantages, aptamer have been slow to 
reach the marketplace with only one aptamer-based drug[5] that’s been approved and 
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applied clinically so far. Some aptamers that are being developed have great potential to 
expand the society with a different option for clinical treatments. Aptamers can be used 
for therapeutic purpose in the same way as antibodies, but with easier approaches to be 
developed and produced. Very like monoclonal antibodies[6], aptamers can theoretically 
be used therapeutically in any disease for which extracellular blockade of protein-protein 
interactions is required. In general, nuclease-mediated degradation is the challenge for 
aptamers work as a drug. So far, some SELEX experiments for therapeutic use 
oligonucleotides that are chemically modified [7-10]. 
During my studies with yeast-cell SELEX for isolating aptamers, I realized the pivotal 
role of a successful selection of great aptamers for therapeutic purposes is truly relying on 
how target proteins are expressed and displayed to expose its ligand binding sites/ 
important domains for aptamer selections. 
The aptamer gets selected against the important ligand binding site may have phenomenal 
role for disease treatments. 
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APPENDIX 1 
 
PROTEIN ENGINEERING TO ENGINEERED Β1 INTEGRIN I-LIKE 
DOMAIN WITH FUSION OF SINGLE-CHAIN IGG-FC INTO A HIGH-
STABILITY FORM, ANCHORD-I-LIKE DOAMIN, FOR DELIVERY 
PURPOSE 
 
Summary 
 
Integrins are non-covalently associated αβ heterodimeric cell surface receptors 
that mediate cell-cell and cell-extracellular matrix adhesions[1], signaling 
bidirectionally across the plasma membrane[2]. Intercellular adhesion molecule-1 
(ICAM-1) is the ligand for αLβ2 integrin (lymphocyte function associated antigen-1; 
LFA-1). The intermolecular binding interaction of these two molecules happens within 
the single domains called α I domain of the integrin and the first domain (D1) at the 
N-terminal domain of ICAM-1. I previously engineered the I domain into high affinity 
while preserving the native sequence in the C-terminal α7-helix, whose downward 
displacement is linked to allosteric activation of integrins[3].  
Integrins play important roles in development, immune cell trafficking and 
responses, and homeostasis. In recent years, great progress has been made towards 
targeting integrins in cancer treatment, and clinical studies with various integrin 
inhibitors have demonstrated their effectiveness in blocking cancer progression. It will 
be valuable to investigate Integrin inhibitor such as DNA aptamers for contributing the 
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society a potentially new path for cancer drug.  
This appendix describes the preliminary results and analyses of β1 anchored-I 
domain engineering for its potential application to work as a target for yeast-cell 
SELEX and a fusion to human ScFc-IgG1 for the carrier of a tool of drug delivery. The 
anchored-I domain from β1 integrin subunit, in this appendix, was engineered by 
stability design and validated through yeast surface display system. The final goal of 
this study has been to use the engineered high affinity anchored-I domain as a 
platform to develop function-blocking inhibitors, therapeutic aptamers that specifically 
or preferentially antagonize the active conformation of β1 integrins.  
 
Introduction and Significance 
 
ICAM-1 (Intercellular Adhesion Molecule 1) also known as CD54 (Cluster of 
Differentiation 54) is a protein that in humans is encoded by the ICAM1 gene.[4] This 
gene encodes a cell surface glycoprotein which is typically expressed on endothelial 
cells and cells of the immune system. It binds to integrins of type CD11a / CD18, or 
CD11b / CD18 and is also exploited by rhinovirus as a receptor. The intercellular 
adhesion molecule (ICAM) 1 is an Ig-like cell adhesion molecule expressed by several 
cell types, including leukocytes and endothelial cells. It can be induced in a cell-
specific manner by several cytokines, for example, tumor necrosis factor-alpha (TNF-
α), interleukin-1(IL-1), and interferon-gamma(IFN-γ), and inhibited by 
glucocorticoids. Its ligands are the membrane-bound integrin receptors LFA-1 and 
Mac-1 on leukocytes, CD43, the soluble molecule fibrinogen, the matrix factor 
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hyaluronan, rhinoviruses, and Plasmodium falciparum malaria-infected erythrocytes. 
ICAM-1 expression is predominantly transcriptionally regulated. ICAM-1 plays an 
important role in inflammatory processes and in the T-cell mediated host defense 
system. It functions as a costimulatory molecule on antigen-presenting cells to activate 
MHC class II restricted T-cells, and on other cell types in association with MHC class 
I to activate cytotoxic T-cells. ICAM-1 on endothelium plays an important role in 
migration of (activated) leukocytes to sites of inflammation. ICAM-1 may play a 
pathogenetic role in rhinovirus infections. Derangement of ICAM-1 expression 
probably contributes to the clinical manifestations of a variety of diseases, 
predominantly by interfering with normal immune function. Among these diseases, 
most of them are malignancies (e.g., melanoma and lymphomas), such as many 
inflammatory disorders (e.g., asthma and autoimmune disorders), atherosclerosis, 
ischemia, certain neurological disorders, and allogeneic organ transplantation. 
Interference with ICAM-1 leukocyte interaction using mAbs, soluble ICAM-1, 
antisense ICAM-1 RNA, and in the case of melanoma mAb-coupled immunotoxin, 
may offer therapeutic possibilities in the future. Integration of knowledge concerning 
membrane-bound and soluble ICAM-1 into a single functional system is likely to 
contribute to elucidating the immunoregulatory function of ICAM-1 and its 
pathophysiological significance in various disease entities[5]. 
Previously, I have engineered the I domain into a high binding-affinity version, 
F265S/F292G mutants of LFA-1 I domains (Id-HA) [3], and were able to successfully 
purify the protein by getting it expressed in E. coli BL21 (DE3) (Novagen), refolded, 
and purified as previously described[6]. I also noticed the purified Id-HA showed fast 
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degradation after purification. In this report, I have documented the preliminary results 
and analyses of the newly engineering Id-HA, β1 anchored-I domain (AncId-HA), for 
its potential application to work as a target for yeast-cell SELEX and a fusion to 
human Sc-Fc-IgG1 for the carrier of a tool of drug delivery. 
 
Experimental Procedures 
 
Transfection 
The day before transfection, 1–3 × 105 cells in complete growth medium were 
prepared in each 35-mm dish and incubated at 37°C (5% CO2) overnight. Cells were 
grown 50–80% confluent before transfection after overnight incubation. For each 35-
mm dish to be transfected, 100 µl serum-free medium (Advanced DMEM) were 
placed into a sterile tube. 3 µl GeneJuice®  Transfection Reagent were added dropwise 
directly to the serum-free medium, mixed thoroughly by vortexing, and incubate at 
room temperature for 5 min. For each 35-mm dish to be transfected, 1 µg DNA were 
added to GeneJuice reagent/serum-free medium mixture and mixed by gentle pipetting. 
Afterwards, GeneJuice reagent/DNA mixture was incubated at room temperature for 
5–15 min. The entire volume of GeneJuice reagent/DNA mixture were added drop-
wise to cells in complete growth medium and dispersed drops over entire surface of 
dish followed by incubating cells for 24–72 h at 37°C (5% CO2). Analyze cells after 
harvest. 
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Immunofluorescence Flow Cytometry.  
Antibodies used in this study were the anti-c-Myc antibody 9E10 (ATCC), rh-ICAMI-
Fc (R&D), and phycoerythrin-labeled goat polyclonal anti-murine antibodies 
(Santa Cruz Biotechnology). After induction, yeast cells were harvested, washed in 
100 μl of the labeling buffer (PBS containing 0.5% BSA with 10 mM MgCl2 or 10 
mM EDTA), and then incubated with ligands in 50 μl of the labeling buffer for 20 min 
with shaking at 30 °C. Cell were then washed and incubated with secondary antibodies 
at 5 μg∕mL in 50 μl of the labeling buffer for 20 min at 4 °C. Finally, cells were 
washed once in 100 μl and suspended in 100 μl of the labeling buffer for flow 
cytometry (Epics XL flow cytometer, Beckman Coulter). 
 
Results 
 
The design of Anchored-I domain 
AncId-HA, the new version of Id-HA, was designed to complement the stability 
of the purified protein of Id-HA (F265S/F292G) and serve as a potential target of 
yeast-cell SELEX. In an effort to create a tool for drug delivery and characterize the 
newly-design protein, two versions of Id-HA were designed (Fig. 1). In the design, I 
replaced the 311 Glycine with a Cystein and extended five amino acids at the N-
terminal from the original Id-HA to create AncId-HA. From the design, the high-
affinity binding of the Id-HA to ICAMI-I had been maintained and also the virtue of 
having a hypothetical disulfide bond could also stabilize the α7-helix in an open 
position.  
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Figure A-1. Characterizations of I domain fusion proteins. 
(a&b) Single letter amino acid sequences and domain demarcations of the fusion 
proteins, Fc-AncId-HA (a) and AncId-HA (b). 
 
 
Characterization of Fc-AncId-HA protein in mammalian-cell system  
To test if the newly design Fc-AncId-HA can be functionally expressed in 
mammalian-cell system, I have constructed the fusion proteins into vector pHIV-
EGFP and transfected the DNA with GeneJuice®  Transfection Reagent (EMD 
Millipore) to Hela cells to observe the characterizations of the proteins. After 
transfection,  the fluorescent intensity of EGFP protein was observed and indicated 
that the Fc-AncId-HA protein was expressed and folded properl and functionally 
(Figure A-2a). Furthermore, I also constructed the newly designed AncId-HA to 
vector pNL6 and expressed the protein through YSD system as previously described[7] 
to examine the binding affinity of AncId-HA to ICAMI in detail. Preliminary, AncId-
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HA showed no binding to CD11 alpha Antibody (TS1/22) when wildtype Id and 
previously engineering αL Id-HA[8] show significant binding (Figure A-3). TS1/22 
was mapped to the ligand binding region of the αL domain (residues Gln-266 and Ser-
270) and competitively inhibits αLβ2 [9, 10]. A possible explanation to the lack of 
binding of TS1/22 to AncId-HA could be the hypothetical disulfide bond has slight 
alternate the steric binding  mechanism of TS1/22 to αL domain- (residues Gln-266 
and Ser-270) but still maintain the binding capability of AncId-HA to ICAM-I (Figure 
A-3). 
A quick comparison of binding affinity in both Id-HA and AncId-HA has been 
performed based on previously described method. Due to the conformation of Id-HA 
and AncId-HA expressed in yeast, the yeast cells can bind to Hela cells (Figure A-2b). 
By comparing the yeast binding capacity to Hela cells can have a quick scan for 
distinguishing the binding affinity of AncId-HA and Id-HA to ICAM-I. From the 
result (Figure A-2b), AncId-HA yeast showed almost comparable but slight higher 
numbers of yeast cells binding to Hela cells than Id-HA, which indicated AncId-HA 
may have tighter binding affinity than Id-HA to ICAM-I.
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Figure A-2. Newly engineered AncId-HA can be functionally expressed in 
mammalian cell system and in yeast-surface display system. (a). Fc-AncId-HA was 
constructed in vector pHIV and successfully expressed in Hela cells with the fusing 
EGFP expressed. (b) AncId-HA was constructed in vector pNL6, and the yeast cells 
show binding interaction with Hela cells. Yeast cells appear as small bright spheres in 
the images. 
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Figure A-3. Comparison of binding affinity to ICAM-I. Wildtype Id yeast, αL Id-HA 
yeast, and AncId-HA yeast were used to test the binding with 9E10, TS1/22, and 
rhICAM-1/Fc. Though AncId-HA yeast didn't show binding to TS1/22, it shows the 
strongest binding to rhICAM-1/Fc. 
 
 
Discussion 
 
In murine xenograft models, mAbs directed against tumor-specific antigens 
largely remain in the blood and no more than 20% of the administered dose typically 
interacts with the tumor[11]. This represents probably one of the major limitations 
faced by mAbs. Antibody uptake by the tumor depends on a subtle balance between 
favourable pharmacokinetics and efficient penetration and retention in the targeted 
tissue, and various characteristics of mAbs, such as molecular size, shape, affinity and 
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valency control these properties. mAbs are large molecules that are characterized by 
very long serum half-lives. They far exceed the renal clearance threshold (<70 kDa), 
preventing them from being eliminated through the kidney glomeruli. Moreover, the 
Fc portion of IgG molecules can interact with various receptors expressed at the 
surface of several cell types, which increase their retention in the circulation. Most 
importantly, the Fc portion can interact with the neonatal Fc receptor (FcRn) 
expressed at the surface of several cell types, including vascular endothelium cells, 
monocytes and macrophages as well as with barrier sites such as the blood–brain 
interface, the glomerular filter in the kidneys and the intestinal epithelium[12]. 
Based on the preliminary results, more binding affinity assay can be performed to 
identify the binding affinity to ICAM-1. After being fully characterized, the Fc-AncId-
HA protein can be purified through mammalian system and establish the method for 
adding payloads to the Fc portion to achieve the goal of targeting delivery.
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